### Appendix 1. Search strategy

# A. Search strategy used to identify relevant studies on the magnitude of association between risk factors and severe outcomes of COVID-19

	Stage 1 search for primary studies	Stage 2 search for systematic reviews
Approach	Integration of studies from our team's	Targeted searches when no primary studies on a
	previous review; updated search using	risk factor of importance to NACI were located
	strategies with the highest yield in the original	
	review, and with modifications to include new	
	(long-term) outcomes not included in the	
	original review	
Strategy	Shown in Additional file 1, part B	Shown in Additional file 1, parts C and D
Concepts	Cohort studies, COVID-19, P <sup>2</sup> ROGRESS And	As in stage 1, with inclusion of terms for systematic
	Other Factors, severe short- and long-term	reviews and specific conditions of interest: sickle
	outcomes	cell anemia, thalassemia, cystic fibrosis, asplenia,
		learning disability
Databases	Ovid Medline® ALL 1946- ; Epistemonikos	Ovid Medline® ALL 1946-
(date)	COVID-19 in L-OVE Platform for systematic	(18 February 2021)
	reviews and broad syntheses categorized as	
	reporting on individual predictors of outcomes	
	(2-3 December 2020; updated in Medline for	
	autoimmune conditions, immune compromise,	
	and children 9-13 April 2021)	
Other sources	Websites: Government of Canada's First	Not applicable
(date)	Nations and Inuit Health Branch, Public Health	
	Agency of Canada, Public Health Ontario ICES,	
	United States Centers for Disease Control and	
	Prevention, Public Health England, Johns	
	Hopkins Center for Health Security, European	
	Centre for Disease Prevention and Control,	
	GenderSci Lab COVID Project. <sup>a</sup>	
	(6 January – 3 February 2021; updated for	
	autoimmune conditions, immune compromise,	
	and children 22 April-14 May 2021)	
Limits applied	English and French language; 1 January 2020	English and French language; 1 January 2020 to
	to date of search; Organization for Economic	date of search
	Cooperation and Development countries	

NACI: National Advisory Committee on Immunization

<sup>&</sup>lt;sup>a</sup> Selection of websites informed by NACI and the High Consequence Infectious Disease Working Group

#### B. Main search for primary studies

Database: Ovid MEDLINE(R) ALL 1946 to December 01, 2020

**Date searched:** December 2, 2020; updated 9-13 April 2021 for autoimmune conditions, immune compromise, and pediatrics

- 1 (Risk factor\* or relative risk or odds ratio or between group\* or Regression or multi-variate or multivaria\* or covariate or univariate or co-variate or matching or ANOVA or Analysis of variance or ANCOVA or Correlation or Covariance or Principal Component Analysis or cohort\* or follow-up or prognos\* or predict\*).mp.
- 2 | exp cohort studies/ or (cohort\* or longitudinal or follow-up).mp.
- 3 (clinical data or clinical outcomes or (clinical adj5 (characteristics or features or manifestations))).tw,kf.
- Transsexualism/ or bisexuality/ or exp homosexuality/ or exp disabled persons/ or transgendered persons/ or "transients and migrants"/ or exp refugees/ or exp Cultural Diversity/ or exp Socioeconomic Factors/ or (Metis or Indigenous\* or Aboriginal\* or Amerindian\* or Autochton\* or First Nations or First Nation or Inuit or Innu or Inuk or Inuvialuit or (native\* adj3 (Canadian or American or Alaska)) or tribal or underprivileged or underrepresented or disadvantaged or disadvantage?ness or disparity or disparities or inequit\* or inequalities or deprived or deprivation or minority or minorities or migrant\* or immigrant\* or visual\* impair\* or hearing impair\* or amputat\* or paraplegic\* or quadraplegic\* or wheelchair\* or transsexual\* or homosexual\* or bisexual\* or two spirit\* or gender-questioning or HIV positive or "living with HIV" or shut-in or house-bound or neglected or (battered adj3 (spouse\* or wife\* or partner)) or disabled or "with a disability" or "with disabilities" or transgender\* or poverty or impoverished or working poor or unemploy\* or under-employed or low\* soci\* status or low\* socioeconomic\* or low\* socio-economic\* or low income\* or low-SES or hard-to-house or homeless\* or under-housed or (street adj4 (worker\* or people or child or children or youth)) or (sex adj3 worker\*) or prostitut\* or inner city or downtown core or city core or skid row or alcoholic\* or mental\* ill\* or mental disorder\* or ((drug or substance\*) adj3 (abuse\* or use\* or illegal or illicit or addict\*))).mp.
- 5 | 1 or 2 or 3 or 4
- 6 (Mortal\* or fatal\* or death\* or died or discharged alive or poor prognos\* or good prognos\* or clinical outcome\* or adverse outcome\* or disease course or clinical course or ((severe\* or serious\* or critical\*) adj4 (ill\* or outcome\* or course or case or cases or patient\* or condition)) or Severity or ((ICU or hospital or intensive care) adj7 (admission\* or admit\*)) or Ventilator\* or ventilation or Hospitaliz\* or hospitalis\* or (Length adj3 stay)).mp.
- (Quality of life or QOL or HRQoL or EDQ5 or EQ-5D or SF-36 or SF-36 or SF-12 or SF12 or longhaul\* or long-haul or ((longterm or long-term) adj4 (consequences or symptoms or sequelae or disabilit\* or function\*)) or stroke or ((lung\* or kidney\* or cardiac or heart) adj3 injur\*) or functional status or post-discharge or ("after" adj3 discharge\*) or ((function\* or disability) adj5 (questionnaire\* or self-report\* or score or index or indices))).mp.
- 8 ((pregnan\* or maternal or perinatal or birth or neonat\* or infant\*) adj7 outcome\*).mp.
- 9 6 or 7 or 8
- (Coronavirus\* or corona-virus\* or betacoronavirus\* or nCOV\* or 2019nCoV or 2019-ncov or covid or covid19 or SARS-CoV\*or SARSCov\*).mp.
- (exp China/ or Iran/ or exp Russia/ or India/ or Pakistan/ or Bangladesh/ or Argentina/ or exp Africa/) not (canada/ or exp united states/ or europe/ or austria/ or belgium/ or exp france/ or exp germany/ or exp united kingdom/ or exp italy/ or spain/ or netherlands/ or exp "scandinavian and nordic countries"/ or australia/ or new zealand/ or mexico/ or chile/ or colombia/ or exp japan/ or korea/ or exp "republic of korea"/ or baltimore/ or berlin/ or boston/ or chicago/ or "district of columbia"/ or london/ or los angeles/ or new orleans/ or new york city/ or paris/ or philadelphia/ or rome/ or san francisco/ or estonia/ or latvia/ or lithuania/ or czech republic/ or hungary/ or poland/ or slovakia/ or slovenia/ or greece/ or luxembourg/ or portugal/ or switzerland/ or israel/ or turkey/)
- ((China or wuhan or hubei or beijing).tw,kf. and china.in.) not (canada or italy or italian or spain or spanish or france or french or united kingdom or UK or england or english or NHS or ireland or irish or wales or welsh or scotland or scottish or german\* or austria\* or sweden or swedish or netherlands or norwegian or norway or finland or finnish or denmark or danish or european or belgium or belgian or Czech or Estonia\* or Greece or

	Greek or Hungar* or Latvia* or Lithuania* or Luxembourg or Iceland* or Poland or Portugal or Slovak Republic or Slovenia* or Switzerland or Japan* or Tokyo or Korea* or Seoul or Chile* or Colombia* or Mexico or Mexican or Israel* or Turkey or Turkish or australia* or new zealand* or united states or USA or american or "U.S." or new york or california* or washington or seattle).tw,kf.
13	((russia* or iran* or tehran or brazil* or India or Pakistan or Argentin* or South Africa* or Nigeria* or Morocc* or Ethiopia*) not (canada or italy or italian or spain or spanish or france or french or united kingdom or UK or england or english or NHS or ireland or irish or wales or welsh or scotland or scottish or german* or austria* or sweden or swedish or netherlands or norwegian or norway or finland or finnish or denmark or danish or european or belgium or belgian or Czech or Estonia* or Greece or Greek or Hungar* or Latvia* or Lithuania* or Luxembourg or Iceland* or Poland or Portugal or Slovak Republic or Slovenia* or Switzerland or Japan* or Tokyo or Korea* or Seoul or Chile* or Colombia* or Mexico or Mexican or Israel* or Turkey or Turkish or australia* or new zealand* or united states or USA or american or "U.S." or new york or california* or washington or seattle)).tw,kf.
14	((china or russia or iran or tehran or Brazil or India or Pakistan or Argentin* or South Africa* or Nigeria* or Morocc* or Ethiopia*) not (canada or italy or italian or spain or spanish or france or french or united kingdom or UK or england or english or NHS or ireland or irish or wales or welsh or scotland or scottish or german* or austria* or sweden or swedish or netherlands or norwegian or norway or finland or finnish or denmark or danish or european or belgium or belgian or Czech or Estonia* or Greece or Greek or Hungar* or Latvia* or Lithuania* or Luxembourg or Iceland* or Poland or Portugal or Slovak Republic or Slovenia* or Switzerland or Japan* or Tokyo or Korea* or Seoul or Chile* or Colombia* or Mexico or Mexican or Israel* or Turkey or Turkish or australia* or new zealand* or united states or USA or american or "U.S." or new york or california* or washington or seattle)).in.
15	(intervention* or therap* or treatment* or management).ti. and (review or trial or guidelines).ti,pt.
16	(case reports/ or (case-stud* or case-report*).jw. or (case-study or (case-report not case-report form*)).mp.) not (case-series or case-control).mp.
17	(5 and 9 and 10) not (11 or 12 or 13 or 14 or 15 or 16)
18	limit 17 to yr="2020 -Current"
19	limit 18 to (english or french)
20	limit 19 to (comment or editorial or historical article or news or newspaper article)
21	19 not 20

Database: Epistemonkos COVID-19 in L-OVE Platform, Inception-December 3, 2020

Date searched: December 3, 2020

Included studies categorized as "individual predictors of outcome".

#### C. Initial scoping search for systematic reviews

Database: Ovid MEDLINE(R) ALL 1946 to Sept 11, 2020

Date searched: September 12, 2020

1	(Risk factor* or relative risk or odds ratio or between group* or Regression or multi-variate or multivaria* or
1	covariate or univariate or co-variate or matching or ANOVA or Analysis of variance or ANCOVA or Correlation or
	Covariance or Principal Component Analysis or cohort* or follow-up or prognos* or predict*).mp.
2	exp cohort studies/ or cohort*.mp.
3	("Associated with" or "Association of" or "impact of" or "Correlated with" or "Impact* on" or characteristics or
	characterise or features or clinical findings or clinical outcomes or clinical manifestations or clinical course).ti.
4	(clinical data or (clinical adj5 (characteristics or features or manifestations))).tw,kf.
5	1 or 2 or 3 or 4
6	(Mortal* or fatal* or death* or died or discharged alive or poor prognos* or good prognos* or clinical outcome*
0	or adverse outcome* or disease course or clinical course or ((severe* or serious* or critical*) adj4 (ill* or
	outcome* or course or case or cases or patient* or condition)) or Severity or ((ICU or hospital or intensive care)
	adj7 (admission* or admit*)) or Ventilator* or ventilation or Hospitaliz* or hospitalis* or (Length adj3 stay)).mp.
7	
	((pregnan* or maternal or perinatal or birth or neonat* or infant*) adj7 outcome*).mp.
8	6 or 7
9	5 and 8
10	(Coronavirus* or corona-virus* or betacoronavirus* or nCOV* or 2019nCoV or 2019-ncov or covid or covid19 or
	SARS-CoV*or SARSCov*).mp.
11	limit 10 to yr="2020 -Current"
12	limit 11 to abstracts
13	(11 not 12) and (1 or 2 or 3 or 4 or 6 or 7)
14	9 and 11
15	13 or 14
16	(pubmed or medline or cochrane or scopus or cinahl).tw. or ((systematic* or evidence-based or scoping or
	umbrella or rapid) adj3 (review* or overview*)).pt,mp,jw. or meta-analy*.pt,mp. or (meta-analy* or metaanalys*
	or research-synthesis).tw. or search*.ab. or (hta or technology assessment).mp,jw.
27	15 and 16
18	limit 17 to (english or french)
_	

Database: Epistemonkos COVID-19 in L-OVE Platform, Inception-December 3, 2020

Date searched: September 12, 2020

Included reviews and broad syntheses categorized as "individual predictors of outcome".

## D. Targeted searches for evidence gaps

Database: Ovid MEDLINE(R) ALL 1946 to February 17, 2021

Data searched: February 18, 2021

31	14 or 18 or 22 or 26 or 30 (180)
30	10 and 29 (54) no duplicates
29	27 or 28 (126771)
28	((intellectual* or learning or developmental) adj2 disab*).ti,ab,kf. (33796)
27	learning disabilities/ or exp intellectual disability/ (110479)
26	10 and 25 (10) 7 without duplicates
25	or/23-24 (33334)
24	(aspleni* or hypospleni* or splenectom*).ti,ab,kf. (25463)
23	Splenectomy/ (21856)
22	10 and 21 (58) 55 without duplicates
21	or/19-20 (53420)
20	(cystic fibrosis or fibrocystic).ti,ab,kf. (48131)
19	Cystic Fibrosis/ (35986)
18	10 and 17 (24) 18 without duplicates
17	or/15-16 (28112)
16	thalassemi*.ti,ab,kf. (18243)
16	exp Thalassemia/ (23108)
15	10 and 13 (45) 42 without duplicates
13	or/11-12 (29702)
12	sickle cell.ti,ab,kf. (25749)
11	exp Anemia, Sickle Cell/ (22908)
10	limit 9 to (english or french) (48382)
9	limit 8 to yr="2019 -Current" (49600)
8	1 and 7 (53864)
7	or/2-6 (9191992)
	(Length adj3 stay)).mp. (3625824)
	or intensive care) adj7 (admission* or admit*)) or Ventilator* or ventilation or Hospitaliz* or hospitalis* or
	(ill* or disease* or outcome* or course or case or cases or patient* or condition)) or Severity or ((ICU or hospital
	outcome* or adverse outcome* or disease course or clinical course or ((severe* or serious* or critical*) adj4
6	(Mortal* or fatal* or death* or died or discharged alive or poor prognos* or good prognos* or clinical
5	(clinical data or (clinical adj5 (characteristics or features or manifestations))).tw,kf. (405780)
	(1197372)
-	characterise or features or clinical findings or clinical outcomes or clinical manifestations or clinical course).ti.
4	("Associated with" or "Association of" or "impact of" or "Correlated with" or "Impact* on" or characteristics or
3	exp cohort studies/ or cohort*.mp. (2391946)
	Covariance or Principal Component Analysis or cohort* or follow-up or prognos* or predict*).mp. (6114068)
2	(Risk factor* or relative risk or odds ratio or between group* or Regression or multi-variate or multivaria* or covariate or univariate or co-variate or matching or ANOVA or Analysis of variance or ANCOVA or Correlation or
	SARS-CoV*or SARSCov*).mp. (118913)
1	(Coronavirus* or corona-virus* or betacoronavirus* or nCOV* or 2019nCoV or 2019-ncov or covid or covid19 or

Appendix 2. Details of the synthesis approach and summary of all findings from the updated rapid review

### A. Approach to synthesis and drawing conclusions

Stage of review	Approach and considerations
Synthesis	Estimated the magnitude of association based on the studies contributing the most events (or largest sample size if events unavailable)
	Compared the findings to other studies based on relevancy (i.e., most well and suitably adjusted, taking place in universal healthcare countries)
	3. Mapped and considered potential overlap across studies conducted in the same country
	4. Two research leads reached consensus on the best estimate of association, and
	categorized the magnitude of association (informed by aOR, aRR, or aHR) as:
	<ul> <li>Little-to-no: &lt;2.0 for increase, &gt;0.50 for reduction</li> </ul>
	<ul> <li>Large: 2.0 to 3.0 for increase, 0.50 to 0.26 for reduction</li> </ul>
	<ul> <li>Very large: ≥4.0 for increase, &lt;0.25 for reduction</li> </ul>
Drawing conclusions	Two research leads reached consensus on the certainty of each estimated association. All exposure-outcome comparisons started at high certainty. We rated down for:
	1. <b>Risk of bias:</b> (a) lack of adjustment for social factors; (b) the expectation of attenuated magnitude of association when the model was adjusted for laboratory values and/or symptoms; (c) for the hospitalization outcome, potential for testing bias in certain populations (e.g., healthcare providers), where the exposure group may have had less severe disease than those not exposed; (d) use of historical, potentially inaccurate, data for risk factors or covariates.
	Inconsistency: for example, different magnitude of association across studies or populations; inadequate number of studies to demonstrate consistency.
	3. <b>Imprecision:</b> for example, small sample size; one study with a wide confidence interval indicating the possibility of two or more different conclusions.
	4. <b>Indirectness:</b> for example, all studies from countries without universal healthcare; inclusion of conditions that may not be directly applicable (e.g., need to extrapolate from different age groups than that of primary interest).

aHR=adjusted hazard ratio; aOR=adjusted odds ratio; aRR=adjusted risk ratio

### B. Summary of findings for multivariate-adjust associations

**Table A2.1.** Summary of findings for multivariate-adjusted associations between risk factors and severe outcomes of COVID-19 among the general population

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).  Hospitalization Mortality				
Age & sex/gender	Hospitalization	Wortality			
60-69 years vs. <60 years	+ (low)	(moderate) / II (low)			
Male vs. female	- (low)	+ (moderate) / ++ (low) - (moderate)			
High risk of exposure due to occupation	- (IOW)	- (moderate)			
Healthcare worker vs. non-healthcare worker	- (low)				
	- (IOW)				
Patient facing healthcare worker vs. non-	+ (low)				
patient facing healthcare worker					
Household member of patient-facing vs. non- patient facing healthcare worker	uncertain				
Immunocompromised: cancer or cancer treat	mont (procent vs. absent)				
•	present vs. absent)	- (moderate)			
Malignancy Chemotherapy in the past 12 months (Grades		- (moderate)			
A-C) <sup>a</sup>		+ / ++ (low)			
Radiotherapy in the past 6 months		+ (low)			
Immunocompromised: transplant (present vs	. absent)				
Recent bone marrow or stem cell transplant		+ (low)			
Solid organ transplant, excluding kidney		- (low)			
Kidney transplant (due to stage 5 kidney		L (low)			
disease)		+ (low)			
Immunocompromised: immunosuppression o	r immunodeficiency (present vs. ak	osent)			
Immunodeficiency or immunosuppression (unspecified)	- (moderate)	- (moderate)			
Sickle cell disease or severe		+ (low)			
immunodeficiency		. (1011)			
Autoimmune conditions (present vs. absent)	1	1			
Rheumatoid arthritis or systemic lupus		- (moderate)			
erythematosus		(moderate)			
Inflammatory rheumatic diseases (any)	- (moderate)				
Rheumatoid arthritis	- (moderate)				
Spondyloarthritis	- (low)				
Connective tissue disease	- (low)				
Vasculitis	+ (low)				
Pre-existing conditions: number of comorbidi					
1 vs. no comorbidities	+ (low)				
2 or more vs.no comorbidities	++ (low)				
Pre-existing conditions: underweight, overwe	· · · · · · · · · · · · · · · · · · ·				
Underweight vs. normal weight	- (low)				
Overweight vs. normal weight	- (low)				
Obesity (all classes) vs. normal weight	+ (low)				
Obesity class I vs. normal weight	- (low)				
Obesity class II or III vs. normal weight	+ (low)				

3.0), very large association (++; >3.0).   Hospitalization   Mortality	
Pre-existing conditions: cardiovascular (present vs. absent)         Congenital heart disease       - (low)       - (moderate)         Cardiovascular disease       - (low)       - (moderate)         Peripheral vascular disease       - (low)       - (moderate)         Hypertension       - (low)       - (moderate)         Stroke       - (low)       - (moderate)         Thromboembolism       - (moderate)       - (moderate)         Congestive heart failure       - (low)       - (moderate)         Heart failure       - (low)       - (moderate)         History of pneumonia       - (low)       - (moderate)         Asthma       - (moderate)         Chronic obstructive pulmonary disease       - (low)       - (moderate)	
Congenital heart disease - (low)  Coronary artery disease - (low) - (moderate)  Peripheral vascular disease - (low)  Atrial fibrillation - (moderate)  Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Cardiovascular disease - (low) - (moderate)  Peripheral vascular disease - (low) - (moderate)  Hypertension - (low)  Atrial fibrillation - (moderate)  Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Coronary artery disease - (low) - (moderate) Peripheral vascular disease - (low)  Hypertension - (low)  Atrial fibrillation - (moderate) Stroke - (low) - (moderate) Thromboembolism - (moderate) Congestive heart failure - (moderate) Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate) Chronic obstructive pulmonary disease - (low) - (moderate)	
Peripheral vascular disease - (moderate)  Hypertension - (low)  Atrial fibrillation - (moderate)  Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Hypertension - (low)  Atrial fibrillation - (moderate)  Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Atrial fibrillation - (moderate)  Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Stroke - (low) - (moderate)  Thromboembolism - (moderate)  Congestive heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Thromboembolism - (moderate)  Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Congestive heart failure - (moderate)  Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Heart failure - (low)  Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Pre-existing conditions: respiratory (present vs. absent)  History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
History of pneumonia - (low)  Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Asthma - (moderate)  Chronic obstructive pulmonary disease - (low) - (moderate)	
Chronic obstructive pulmonary disease - (low) - (moderate)	
Pulmonary hypertension or fibrosis - (low)	
Bronchiectasis, cystic fibrosis, or alveolitis - (moderate)	
Pre-existing conditions: endocrine (present vs. absent)	
Type 1 diabetes + (moderate) / ++ (lov	v)
Type 2 diabetes + (moderate) / ++ (lov	
Diabetes (any) - (low)	,
Pre-existing conditions: renal (present vs. absent)	
Chronic kidney disease + (low) - (moderate)	
End-stage kidney disease + (moderate)	
End-stage kidney disease with dialysis + (moderate) / ++ (lov	v)
Pre-existing conditions: hepatic (present vs. absent)	,
Cirrhosis - (low)	
Pre-existing conditions: neurological (present vs. absent)	
Alzheimer's disease or dementia uncertain	
Dementia + (moderate)	
Parkinson's disease + (low)	
Epilepsy + (moderate)	
Motor neuron disease multiple sclerosis	
myasthenia gravis, or Huntington's disease + (moderate)	
Cerebral palsy + (low)	
Pre-existing conditions: other (present vs. absent)	
Down Syndrome + (moderate) / ++ (low) ++ (moderate)	
Intellectual disability (excluding Down	
Syndrome) - (moderate)	
Osteoporotic fracture (hip, spine, wrist) - (moderate)	
Severe mental illness - (moderate)	
Frailty (present vs. absent) b	
Pre-frailty - (low)	
Frailty + (low)	
Other factors	

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).			
	Hospitalization	Mortality		
Past or current vs. never smoking	- (low)			
Higher vs. lower alcohol consumption	- (low)			
Low vs. adequate physical activity	- (low)			

<sup>&</sup>lt;sup>a</sup> There was evidence of a large to very large increase in mortality with grades B and C chemotherapy from one large study. However, the stages of chemotherapy were not defined, and could not be ascertained from the study's authors. In the absence of adequate information, we have grouped all stages of chemotherapy (A, B, and C) together for analysis.

<sup>&</sup>lt;sup>b</sup> General population sample that may include community and non-community dwelling people. Measured on scales that include items such as weight loss, exhaustion, physical activity, walking speed, grip strength, overall health, disability, presence of disease, dementia, falls, mental wellbeing.

**Table A2.2.** Summary of findings for multivariate-adjusted associations between risk factors and severe outcomes of COVID-19 among people with laboratory-confirmed COVID-19

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; $\leq 2.0$ ), large association (+; $\leq 2.0$ ), very large association (++; $\leq 3.0$ ).					
	Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Age & sex/gender						
60-69 years vs. <60 years	+ (moderate)	uncertain	+ (low)	+ to ++ (low)	+ (moderate) / ++ (low)	
Children (0-18 years) vs. adults (18-44 years)	- (low)			- (low)		
Children (0-19 years) vs. adults (50-59 years)	+ reduction (low)					
Children <1 month vs. >1 month		- (low)				
Sex or gender identity					•	
Male vs. female	- (moderate)	- (low)	- (low)	- (moderate)	- (high)	
Among children: male vs. female	- (low)	- (low)	- (low)	- (low)		
Among children, race or ethnicity						
Black vs. White			- (low)			
Black vs. White non-Hispanic	+ (low)			+ (low)		
Hispanic/Latino vs. White non-Hispanic	- (low)			- (low)		
Asian vs. White non-Hispanic	- (low)			- (low)		
Hawaiian/Pacific Islander vs. White non-Hispanic	- (low)			- (low)		
Alaskan/American Indian vs. White non-Hispanic	- (low)			- (low)		
Pregnancy (present vs. absent)						
Pregnancy (any stage)	+ (low)	+ (low)	+ (low)		- (low)	
High risk of exposure due to occupation						
Healthcare worker vs. non-healthcare worker	+ reduction (low)	+ reduction (low)				
Patient facing healthcare worker vs. non-patient facing healthcare worker	uncertain	uncertain				
Immunocompromised (present vs. absent)	·					
Malignancy (any type, severity, or stage)	- (moderate)	- (low)	- (low)	- (moderate)	- (low)	
Metastatic cancer among those age <70 years					+ (low)	
Active cancer treatment	uncertain	uncertain	uncertain		uncertain	
History of cancer without current treatment	- (low)	- (low)	- (low)		- (low)	

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).					
	Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Solid organ transplant					+ (low)	
Transplant (any type)	+ (low)					
Human immunodeficiency virus	uncertain			uncertain	- (moderate)	
Immunosuppression (unspecified)	- (moderate)			uncertain	- (low)	
Among children, immunodeficiency or immunosuppression	+ (low)	- (low)	uncertain	+ to ++ (low)		
Among children, malignancy			+ (low)			
Autoimmune conditions (present vs. absent)						
Autoimmune diseases (general)	- (low)					
Rheumatic diseases and connective tissue disorders <sup>a</sup>	- (low)	- (low)	- (low)	- (moderate)	- (moderate)	
Inflammatory bowel disease	- (low)	- (low)		- (low)	- (low)	
Multiple sclerosis				uncertain		
Pre-existing conditions: number of comorbidities						
1 vs. no comorbidities	- (moderate)	uncertain	uncertain		- (low)	
2 or more vs. no comorbidities	+ (moderate)	+ (low)	+ (low)		+ (moderate)	
Among children, 1 vs. no comorbidities <sup>b</sup>	+ (low)					
Among children, 1 or more vs. no comorbidities <sup>c</sup>		+ (low)	+ (low)	+ (low)		
Among children, 2 or more vs. no comorbidities <sup>b</sup>	+ (moderate)					
Pre-existing conditions: underweight, overweight, and obesi	ty					
Underweight vs. normal weight	uncertain		uncertain		- (low)	
Underweight vs. normal weight, overweight, or class I obesity					- (low)	
Overweight vs. normal weight	- (moderate)		- (low)	- (low)	- (moderate)	
Obesity class I vs. normal weight					- (moderate)	
Obesity class II vs. normal weight					- (low)	
Obesity class I or II vs. normal weight	- (moderate)					
Obesity class III vs. normal weight	- (low)				+ (low)	
Obesity (all classes) vs. normal weight			- (low)	- (low)		
Obesity (all classes); present vs. absent	- (moderate)			- (low)	- (high)	
Obesity class III; present vs. absent	+ (low)					
Among children, obesity	uncertain	- (low)		uncertain		

	M	agnitude of associa	ation (certainty in a	ssociation), by outcor	ne	
	Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association $(-; \le 2.0)$ , large association $(+; \ge 2.0)$ , very large association $(+; \ge 2.0)$ .					
Risk factor vs. comparator						
	Hospitalization	ICU admission	Mechanical	Severe disease	Mortality	
			ventilation			
Pre-existing conditions: cardiovascular (present vs. abse	-					
Atrial fibrillation	- (low)					
Cardiovascular disease	- (low)				- (low)	
Cerebrovascular accident	+ (moderate)					
Cerebrovascular disease	- (moderate)			- (low)	- (moderate)	
Congestive heart failure or heart failure	- (low)				- (moderate)	
Coronary artery disease	- (high)				- (moderate)	
Hyperlipidemia	- (moderate)				- (moderate)	
Hypertension	- (high)			- (low)	- (high)	
Myocardial infarction					- (low)	
Peripheral vascular disease	- (low)				- (low)	
Venous thromboembolism	- (low)					
Among children, cardiovascular disease	? (uncertain)			- (low)		
Among children, hypertension	+ (low)			- (low)		
Pre-existing conditions: respiratory (present vs. absent)	·					
Asthma	- (high)		- (low)		- (high)	
Chronic obstructive pulmonary disease	- (high)		- (low)		- (high)	
Chronic bronchitis	- (low)					
Interstitial lung disease	uncertain					
Obesity hypoventilation	- (low)		+ (low)		- (low)	
Rhinitis or rhinosinusitis	- (low)					
Among children, asthma	- (low)	+ (low)				
Pre-existing conditions: endocrine (present vs. absent)	<u> </u>					
Diabetes (any)	- (low) <sup>d</sup>		- (low)	- (low)	- (moderate)	
Glycosylated hemoglobin <7.5 vs. ≥7.5%					- (low)	
Diabetes (any) in females					+ (low)	
Hypothyroidism	- (low)					
Among children, diabetes	? (uncertain)	- (low)		- (low)		
Among children, endocrine condition	,		+ (low)	·		
Pre-existing conditions: renal (present vs. absent)						

	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; $\leq$ 2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).					
Risk factor vs. comparator						
•	Hospitalization	ICU admission	Mechanical ventilation	Severe disease	Mortality	
Kidney disease (any)					- (moderate)	
Chronic kidney disease	- (low) <sup>d</sup>		- (low)		- (low)	
End-stage kidney disease	uncertain					
Dialysis			- (low)		- (low)	
Pre-existing conditions: hepatic (present vs. absent)	•					
Cirrhosis	- (low)		- (low)		- (low)	
Pre-existing conditions: neurological (present vs. absen	t)					
Alzheimer's disease or dementia				- (low)		
Dementia	uncertain				- (moderate)	
Epilepsy				- (low)		
Hemi- or paraplegia					- (moderate)	
Parkinson's disease or movement disorder				- (low)		
Pre-existing conditions: psychiatric (present vs. absent)						
Any mental illness/mood disorder				- (moderate)	- (moderate)	
Depression	- (low)					
Major psychiatric disorder <sup>e</sup>	+ (low)			- (low)	+ (low)	
Pre-existing conditions: other (present vs. absent)						
Disability					- (low)	
Peptic ulcer					- (low)	
Intellectual disability or developmental disorder				- (low)		
Obstructive sleep apnea	- (moderate)		- (low)		- (low)	
Among children, metabolic condition			+ (low)			
Other factors						
Past or current vs. never smoking	- (moderate)		- (low)		- (moderate)	
Higher vs. lower alcohol consumption	- (low)					
Alcohol abuse vs. no alcohol abuse	- (low)		- (low)		- (low)	
Substance abuse vs. no substance abuse	uncertain			uncertain	uncertain	

ICU=intensive care unit

<sup>&</sup>lt;sup>a</sup> There was also low certainty evidence of no increase in renal failure or ischemic stroke with rheumatic disease. These outcomes were not investigated for any other risk factors in this population.

<sup>a</sup> Includes congenital malformations, asthma, epilepsy, complex genetic syndromes, endocrine disorders, cancers, hematologic diseases, rheumatic diseases, autoimmune disease, autism or neurologic development impairment, gastrointestinal diseases, liver disease, renal disease, genitourinary diseases, cystic fibrosis or other chronic lung diseases, metabolic disorders, hydrocephalus, severe obesity, hypertension, otolaryngolic diseases, pregnancy, and 'complex chronic conditions'.

<sup>b</sup> Includes congenital malformations, asthma, epilepsy, complex genetic syndromes, endocrine disorders, cancers, hematologic diseases, rheumatic diseases, autism or neurologic development impairment, gastrointestinal diseases, genitourinary diseases, renal disease, cystic fibrosis or other chronic lung diseases, metabolic disorders, hydrocephalus, severe obesity, otolaryngolic diseases.

<sup>&</sup>lt;sup>c</sup> Approaching a large association (OR 1.8-1.9)

<sup>&</sup>lt;sup>d</sup> Schizophrenia, schizoaffective disorder, or bipolar disorder. Defined by hospital discharge diagnosis, in combination with drug use (filled a prescription) for the condition in the past 6 months.

**Table A2.3.** Summary of findings for multivariate-adjusted associations between risk factors and severe outcomes of COVID-19 among people hospitalized with laboratory-confirmed COVID-19

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).						
	Hospital length of stay	ICU admission	Mechanical ventilation	Severe disease	Acute kidney injury	Mortality	
Age & sex/gender							
60-69 years vs. <60 years	uncertain	- (low)	- (low)	+ (low)	- (moderate)	+ (high)	
Male vs. female	- (low)	- (moderate)	- (moderate)	- (moderate)	- (low)	- (high)	
Among children, male vs. female				- (low)			
Among children, race or ethnicity							
Hispanic or Latino vs. White non-Hispanic				- (low)			
Asian vs. White non-Hispanic				uncertain			
Black vs. White non-Hispanic				- (low)			
High risk of exposure due to occupation	·					•	
Healthcare worker vs. non-healthcare worker		+ reduction (low)					
Immunocompromised (present vs. absent)	<u>.</u>						
Malignancy (any type, severity, or stage) <sup>a</sup>		- (moderate) <sup>a</sup>	- (moderate)	- (moderate)	- (moderate)	- (moderate) <sup>a</sup>	
Transplant (any type)		- (low)					
Solid organ transplant			- (low)	- (low)	+ (low)	- (low)	
Human immunodeficiency virus		- (low)				- (low)	
Immunosuppression or immunodeficiency (unspecified)		- (low)		- (low)	uncertain	- (moderate)	
Autoimmune conditions (present vs. absent)				1	1	•	
Autoimmune disease (any type)		uncertain					
Connective tissue disorder					uncertain		
Rheumatic disease						- (low)	
Chronic inflammatory disease			- (low)			- (low)	
Inflammatory bowel disease <sup>b</sup>			- (low)			- (low)	
Pre-existing conditions: number of comorbidities						_	
1 vs. no comorbidities	- (low)	- (moderate)	- (low)	- (low)		- (moderate)	
2 or more vs. no comorbidities	- (low)	- (low)	- (low)	+ (low)		+ (moderate)	
Among children, chronic condition (present vs. absent)				+ (low)		++ (low)	
Pre-existing conditions: underweight, overweight,	and obesity						

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).						
	Hospital length of stay	ICU admission	Mechanical ventilation	Severe disease	Acute kidney injury	Mortality	
Underweight vs. normal weight			uncertain			- (moderate)	
Underweight vs. normal weight or overweight						- (low)	
Overweight vs. normal weight			- (low)	- (moderate)		- (moderate)	
Obesity class I vs. normal weight			uncertain			- (low)	
Obesity class II vs. normal weight			uncertain			uncertain	
Obesity class I or II vs. normal weight				- (low)		- (low)	
Obesity class II or III vs. normal weight						- (low)	
Obesity class III vs. normal weight			uncertain	uncertain		- (low)	
Obesity (all classes) vs. normal weight			- (low)	- (low)	- (low)	- (low)	
Obesity (all classes); present vs. absent		- (low)			- (low)	- (high)	
Obesity class I or II; present vs. absent			- (low)				
Obesity class III; present vs. absent			uncertain	+ (low)			
Pre-existing conditions: cardiovascular (present vs.	absent)					•	
Atrial fibrillation		- (low)	- (low)	- (low)		- (moderate)	
Cardiomyopathy							
Cardiovascular disease		- (low)		- (moderate)	- (moderate)	- (high)	
Cerebrovascular accident			- (low)	- (low)		- (moderate)	
Cerebrovascular disease		- (low)			- (low)	- (low)	
Congestive heart failure or heart failure		- (moderate)	- (low)	- (low)		- (high)	
Coronary artery disease		- (moderate)	- (moderate)	- (low)		- (high)	
Hyperlipidemia		- (low)	- (low)	- (low)		- (moderate)	
Hypertension		- (moderate)	- (moderate)	- (moderate)	- (moderate)	- (high)	
Myocardial infarction							
Peripheral vascular disease			- (low)	- (low)	- (low)	- (moderate)	
Venous thromboembolism			- (low)	- (low)		- (low)	
Pre-existing conditions: respiratory (present vs. abs	ent)						
Asthma		- (low)	- (moderate)	- (moderate)		- (high)	
Asthma or chronic obstructive pulmonary disease			· ,	,	- (low)		
Chronic lung disease							
Chronic obstructive pulmonary disease			- (moderate)	- (moderate)		- (high)	
Interstitial lung disease		uncertain	· ,	,			
Obstructive lung disease (any)		- (moderate)					

Risk factor vs. comparator	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; $\leq$ 2.0), large association ( ${+}$ ; 2.0 to 3.0), very large association ( ${++}$ ; >3.0).						
·	Hospital length of stay	ICU admission	Mechanical ventilation	Severe disease	Acute kidney injury	Mortality	
Pre-existing conditions: endocrine (present vs. abser	nt)						
Diabetes (any)		- (moderate)	- (moderate)	- (moderate)	- (moderate)	- (high)	
Hypothyroidism			- (low)	- (low)		- (low)	
Pre-existing conditions: renal (present vs. absent)							
Chronic kidney disease		- (moderate)	- (moderate)	- (low)		- (high)	
End-stage kidney disease	- (low)		- (low)			- (moderate)	
Pre-existing conditions: hepatic (present vs. absent)							
Liver disease or cirrhosis						- (moderate)	
Liver disease					- (low)		
Pre-existing conditions: neurological (present vs. abs	sent)				•		
Chronic neurologic disorder						- (moderate)	
Dementia			- (low)	uncertain	- (moderate)	- (low)	
Neurologic disease		- (low)					
Paraplegia					- (low)	uncertain	
Pre-existing conditions: psychiatric (present vs. abse	nt)					•	
Schizophrenia		- (low)				- (low)	
Pre-existing conditions: other (present vs. absent)							
Hematologic disorder						- (low)	
Obstructive sleep apnea		- (low)				- (low)	
Frailty							
Pre-frailty	- (low)	- (low)	- (low)			- (low)	
Frailty	+ (low); - (low) for stay >10 day	+ (low)	- (low)			+ (low)	
Other factors							
Past or current vs. never smoking	- (low)	- (low)	- (low)	- (moderate)	- (low)	- (moderate)	

ICU=intensive care unit

<sup>&</sup>lt;sup>a</sup> Includes hematologic and lymphatic malignancy
<sup>b</sup> Includes inflammatory bowel disease, rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis

**Table A2.4.** Summary of findings for multivariate-adjusted associations between risk factors and severe outcomes of COVID-19 among people admitted to the intensive care unit (all outcomes), or among people mechanically ventilated (mortality only) with laboratory-confirmed COVID-19

	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; ≤2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).						
Risk factor vs. comparator	ICU length of stay	Mechanical ventilation	Severe disease	Acute kidney injury	Mortality (among ICU admitted)	Mortality (among mechanically ventilated)	
Age & sex/gender							
60-69 years vs. <60 years			- (low)	- (low)	- (low)	- (low)	
Male vs. female		uncertain		uncertain	- (moderate)	- (low)	
Immunocompromised (present vs. absent)							
Active malignancy						+ (low)	
Malignancy (any type, severity, or stage)		uncertain		- (low)	- (low)	- (low)	
Transplant (solid organ)		- (low)		- (low)	- (low)		
Immunosuppression (unspecified)					- (low)		
Autoimmune conditions (present vs. absent)							
Systemic inflammatory disease					- (low)		
Pre-existing conditions: number of comorbidities							
1 vs. no comorbidities	- (low)						
2 or more vs.no comorbidities	- (low)						
Pre-existing conditions: underweight, overweight,	, and obesity						
Underweight vs. normal weight						uncertain	
Overweight vs. normal weight				uncertain	uncertain	- (low)	
Obesity class I vs. normal weight				uncertain	- (low)	uncertain	
Obesity class II vs. normal weight				uncertain	uncertain	- (low)	
Obesity class III vs. normal weight				+ (low)	uncertain	- (low)	
Obesity (all classes); present vs. absent					- (low)		
Pre-existing conditions: cardiovascular (present vs	s. absent)						
Chronic heart disease					- (low)		
Coronary artery disease				- (low)	- (low)	- (low)	
Hypertension				- (low)	- (moderate)	- (low)	
Congestive heart failure (or heart failure for mortality among mechanically ventilated)				- (low)	- (low)	- (low)	

	Magnitude of association (certainty in association), by outcome  Magnitude of associations are shown as: uncertain (very low certainty), little-to-no association  (-; $\leq$ 2.0), large association (+; 2.0 to 3.0), very large association (++; >3.0).						
Risk factor vs. comparator	ICU length of stay	Mechanical ventilation	Severe disease	Acute kidney injury	Mortality (among ICU admitted)	Mortality (among mechanically ventilated)	
Pre-existing conditions: respiratory (present vs.	absent)	<del>.</del>					
Asthma					- (low)	- (low)	
Chronic obstructive pulmonary disease					- (low)	- (low)	
Chronic respiratory disease					- (low)		
Pre-existing conditions: endocrine (present vs. a	absent)						
Diabetes (any)				- (low)	- (moderate)	- (low)	
Pre-existing conditions: renal (present vs. absen	nt)						
Chronic kidney disease, any stage					- (low)	- (low)	
Chronic kidney disease, stage III				- (low)			
Chronic kidney disease, stage IV and V				+ (low)			
End-stage kidney disease						- (low)	
Pre-existing conditions: neurological (present vs	s. absent)			<u>.</u>			
Chronic neurologic disorder					- (low)		
Other factors				<u> </u>			
Past or current vs. never smoking					- (low)	- (low)	

ICU=intensive care unit

# C. Findings of Canadian reports

 Table A2.5. All findings from Canadian reports

Outcome (population)	Study	Key findings
Age 60-69 vs. <60 years		
Hospitalization (people with COVID-19)	O'Brien 2020 (a)	<ul> <li>The highest hospitalization rates were in those aged ≥70 years (about 40% in females and 50% in males), with about half this magnitude seen in those 60-69 years.</li> <li>Highly significant differences of approximately 1.5-fold were seen per decade across the 60s, 50s and 40s; at least a 2-fold larger rate is apparent between those in their 60s versus &lt;60 years. About a 4-fold association was seen between those aged ≥60 years and 20-49 years.</li> <li>The associations appeared similar when considering only men or women, although the absolute rates for women were lower across all age groups above 30 years.</li> </ul>
ICU admission (people with COVID-19)	O'Brien 2020 (a)	<ul> <li>The highest ICU admission rates were in those aged 70-79 years (rates significantly lower in the &gt;80 year age group), with smaller rates, but not by a large amount, in those in their 60s.</li> <li>People in their 60s appear to have a 1.5 to 2-fold higher rate of ICU admission compared with those in their 50s, and at least a 2-fold larger rate than those &lt;60 years. About a 3-4 fold association was seen between those ≥60 and 20-49 years.</li> <li>The associations appeared similar when considering only men or women, although the absolute rates for women were lower across all age groups above 30 years.</li> </ul>
Mortality (people with COVID-19)	Fisman 2020 (a)	<ul> <li>In multivariate regression analysis, adjusted odds of mortality (95% CI) by age (per 10 year increment): 2.42 (1.78, 3.29), p&lt;0.001</li> </ul>
	O'Brien 2020 (b)	<ul> <li>Of all closed cases (recovered or died; n = 69,409), the case fatality rate was about 2-4 fold higher I those ≥70 years versus those in their 60s, and at least 2-fold higher for those in their 60s versus 50s. Similar findings were found when considering deaths per 100,000 in the entire Canadian population based on census data.</li> </ul>
	PHAC COVID -19 SET 2020	<ul> <li>The mortality rate was less than 1% in all age groups up until the age of 50 years, and then increased rapidly with age, with a rate of 1.2% for those aged 50 to 59 years, 5.9% in those 60-69, and increasing up to 34.4% for those aged 80 years and over.</li> </ul>
	Wang 2020	<ul> <li>When excluding long-term care residents and people living in shelters, the relative risk of mortality was about 2-fold higher for those in their 60s versus those 50-59 y, although absolute rates were low (0.7 and 0.3%).</li> </ul>

Outcome	Study	Key findings
(population)		
Gender identity/sex		
Hospitalization (people with COVID-19)	O'Brien 2020 (a)	<ul> <li>The rate of hospitalization is lower among females than males in all age categories &gt;30 years. When health care workers, long-term care residents, and school/daycare workers/attendees were excluded, a significant reduction of female cases for hospitalization was only observed in age categories &gt;50 years.</li> </ul>
ICU admission (people with COVID-19)	O'Brien 2020 (a)	<ul> <li>The rate of ICU admission is lower among females than males in all age categories &gt;30 years. When health care workers, long-term care residents, and school/daycare workers/attendees were excluded, a significant reduction of female cases for ICU admission was only observed in age categories &gt;50 years.</li> </ul>
Mortality	O'Brien 2020 (a)	A significantly lower mortality rate was observed in females compared with males within each age category.
(people with COVID-19)	PHAC COVID-19 SET 2020	Case fatality rate was higher among males (8.5%) than females (7.9%).
	Wang 2020	<ul> <li>In both long-term care and non-long-term care settings, the case fatality proportion appeared to be lower among females (2.8 to 22.8% depending on age group in non-long-term care population) compared to males (7.1 to 30.5%).</li> </ul>
Living in long-term care		
Mortality (general population)	Fisman 2020 (b)	<ul> <li>229/1,731,315 (&lt;0.1%) individuals &gt;69 years in the general community-dwelling population and 83/79,498 (0.1%) long-term care residents died (IRR (95% CI) 13.1 (9.9, 17.3)); denominators based on estimates and number of facility beds.</li> <li>Comparisons with other general community-living population ages:         <ul> <li>All adults (n = 14,566,547): 90.4 (68.9, 117.6)</li> <li>Aged ≥60 years (n = 3,447,427): 23.1 (17.6, 30.2)</li> <li>Aged ≥80 years (n = 642,571): 7.6 (5.5, 10.4)</li> </ul> </li> <li>The median IRR (95% CI) for death among long-term care residents compared with community-living adults rose from 8.03 (1.96, 23.32) on March 29 to 87.28 (6.44, 769.76) by April 11, 2020</li> </ul>
Mortality (people with COVID-19)	Fisman 2020 (a)	<ul> <li>Adjusted odds (aOR (95% CI)) of death among cases (n = 1,734) residing in long term care compared with cases residing in the general population in Ontario: 6.24 (2.95, 13.21)</li> </ul>
	Liu 2020	<ul> <li>Ontario (long-term care residences): 1,817 deaths (mortality in those with COVID-19, 30.5%)</li> <li>British Columbia (acute care, long term care and independent living residences): 156 deaths (mortality in those with COVID-19, 33.5%)</li> </ul>
	O'Brien 2020 (b)	<ul> <li>During the first wave of the pandemic and up to the end of May 2020, long term care facilities and retirement homes accounted for more than 80% of all SARS-CoV-2 deaths in Canada.</li> </ul>
	PHAC COVID -19 SET 2020	<ul> <li>Mortality in those with COVID-19 among long-term care residents or those living in seniors' homes compared with those in the general population: 203/758 (26.8%) versus 75/9391 (0.8%).</li> </ul>

Outcome	Study	Key findings
(population)		
	Wang 2020	<ul> <li>Mortality in those with COVID-19 by age group among long term care residents compared with those in the general population:         <ul> <li>Aged 0-59 years: 3/33 (9.1%) versus 6/8,122 (0.1%)</li> <li>Aged 60-79 years: 45/213 (21.1%) versus 34/1,098 (3.1%)</li> </ul> </li> <li>Aged 80+ years: 155/512 (30.3%) versus 35/171 (20.5%)</li> <li>Adjusted risk (aRR (95%CI) of death among cases (n = 13,122) residing in long term care (918/3368, 27.3%) compared with those residing in the general population (516/12,750, 4.0%) in Greater Toronto area: 1.4 (1.1, 1.8), p=0.02 (adjusted for age and sex)</li> <li>Stratified by sex for those aged ≥60 years:         <ul> <li>Males: RR (95% CI) for 60-70 y 2.4 (1.5 – 4.0), 70-80 y 1.3 (1.0 – 1.7) and ≥80 y 1.2 (1.0 – 1.5)</li> <li>Females: RR (95% CI) for 60-70 y) 7.6 (4.3 – 13.3), 70-80 y 1.8 (1.2 – 2.7), and ≥80 y 1.2 (1.0 – 1.5)</li> </ul> </li> </ul>
Homelessness		1.4)
Mortality (people with COVID-19)	Wang 2020	<ul> <li>Adjusted risk (aRR (95% CI) of death among COVID-19 patients (n = 13,122) residing in a shelter (3/372, 0.8%) compared with those residing in the general population in Greater Toronto area (516/12,750, 4.0%): 0.4 (0.0, 2.5), p=0.5 (adjusted for age and sex)</li> </ul>
	Fisman 2020 (a)	<ul> <li>Odds (OR (95% CI)) of death among COVID-19 patients (n = 1,734) who were homeless compared with those in the general population (not homeless): 0.43 (0.18, 1.06), p=0.07</li> </ul>
Living on a First Nations	reserve	
Hospitalization (people with COVID-19)	Indigenous Services Canada 2021	- On First Nations reserves, as of January 6, 2021: 443 hospitalizations in 9,715 cases (4.6%)
Mortality (people with COVID-19)	Indigenous Services Canada 2021	<ul> <li>On First Nations reserves, as of January 6, 2021: 92 deaths in 9,715 cases (0.9%)</li> <li>vs. <a href="https://ipac-canada.org/coronavirus-resources.php">https://ipac-canada.org/coronavirus-resources.php</a> Jan 15, 2021: 17,538 deaths in 688,891 cases (2.5%) (all ages)</li> <li>vs. Public Health Agency of Canada COVID-19 Surveillance and Epidemiology Team 2020 rates in those 0-60 are 0.01% to 1.2%</li> </ul>
Occupational exposure:		
Hospitalization (people with COVID-19)	O'Brien 2020 (a)	<ul> <li>Of all healthcare workers (n = 21,367): 407 (1.9%) were hospitalized and 16,631 (77.8%) were not hospitalized (not reported for 19.5%).</li> <li>Compared with people having any occupation and non-healthcare occupations: within each decade for those 30-70 years, there appears to be at least a 2-fold higher number of cases hospitalized in those with any occupation or other occupations compared with hospitalizations in healthcare workers; absolute numbers in</li> </ul>

Study	Key findings
	each decade (in those 30-70 years) were higher for males, but the trends in associations with other
	occupations were similar between sexes.
O'Brien 2020 (a)	<ul> <li>Of all healthcare workers (n = 21,367): 168 (0.8%) were admitted to ICU</li> </ul>
	<ul> <li>Compared with people having any occupation and non-health are occupations: within each decade for those</li> </ul>
	30-70 years, there appears to be at least a 2-fold higher number of cases admitted to the ICU in those with
	any occupation or other occupations compared with healthcare workers; absolute numbers in each decade
	(in those 30-70 years) were higher for males, but the trends in associations with other occupations were
	similar between sexes.
Fisman 2020 (a)	- Odds (OR (95% CI)) of death among cases (n = 1,734) who were healthcare workers compared with those in
	the general population (not healthcare workers): 0.033 (0.017, 0.063), p<0.001
Fisman 2020 (a)	- Odds (OR (95% CI)) of death among cases (n = 1,734) who work in a homeless shelter compared with those in
	the general population (did not work in a homeless shelter): 0.17 (0.024, 1.25), p=0.08
Subedi 2020	<ul> <li>Age-standardized mortality rates by % visible minority in neighbourhood, per 100,000 population:</li> </ul>
	<ul> <li>Less than 1% visible minority: 16.9</li> </ul>
	o 1 to <10% visible minority: 12.7
	o 10 to <25% visible minority: 27.3
	o 25+% visible minority: 34.5
	- In Ontario and Quebec, rates in neighbourhoods with >25% vs. <1% visible minorities were 3-fold; they were
	10-fold in British Columbia (although absolute numbers much lower in this province)
	Male versus female age-standardized death rate by % visible minority in neighbourhood, per 100,000
	population:
	<ul> <li>Less than 1% visible minority: 18.3 versus 15.6</li> <li>1 to &lt;10% visible minority: 14.7 versus 11.1</li> </ul>
	<ul> <li>10 &lt; 10% visible minority: 14.7 versus 11.1</li> <li>10 to &lt; 25% visible minority: 34.1 versus 22.7</li> </ul>
	o 25+% visible minority: 41.0 versus 29.7
	<ul> <li>Age-standardized mortality rate by % Black, per 100,000 population (Montreal):</li> </ul>
	Less than 1% Black: 88.1
	o 1 to <10% Black: 105.0
	o 10 to <25% Black: 124.7
	o 25+% Black: 149.3
	<ul> <li>Age-standardized mortality rate by % South Asian, per 100,000 population (Toronto):</li> </ul>
	o <1% South Asian: 26.2

Outcome	Study	Key findings
(population)		
		<ul> <li>1 to &lt;10% South Asian: 24.6</li> </ul>
		o 10 to <25% South Asian: 29.5
		- 25+% South Asian: 35.0
Number of comorbiditie	S	
Mortality	O'Brien 2020 (b)	<ul> <li>Of &gt;9,500 COVID-19 involved deaths between March and July 2020, 90% had at least one other cause,</li> </ul>
(people with COVID-19)		condition, or complication reported on the death certificate.
		The proportion of those with at least one other disease or condition reported on the death certificate
		decreases with age, ranging from 93% for those aged 45 to 64 years, to 89% for those aged 85 and older.
	PHAC COVID-19	<ul> <li>Among patients with COVID-19 for whom data were available on pre-existing conditions (cardiac disease,</li> </ul>
	SET 2020	chronic neurological or neuromuscular disorder, diabetes, immunodeficiency disease/condition, liver
		disease, malignancy, renal disease, respiratory disease) (n = 6,350):
		<ul> <li>Aged 0-59 years: none, 0.1%; 1, 1.5%; 2, 0.0%; 3+, 2.6%</li> </ul>
		<ul> <li>Aged 60-79 years: none, 3.1%; 1, 3.8%; 2, 12.8%; 3+, 25.5%</li> </ul>
		<ul> <li>Aged ≥80 years: none, 29.9%; 1, 21.8%; 2, 30.2%; 3+, 37.9%</li> </ul>
		<ul> <li>All ages: none, 1.9%; 1, 5.8%; 2, 17.0%; 3+, 27.9%</li> </ul>
		<ul> <li>Data for risks based long-term care residency indicate that this is an important variable that may have</li> </ul>
		inflated the findings for pre-existing conditions.
Immune compromise		
Mortality	Fisman 2020 (a)	- The adjusted odds of mortality (95% CI) among immune compromised was 3.56 (1.12 to 11.35). This finding
(people with COVID-19)		was adjusted for age, long-term care residency, smoking, renal disease, diabetes, and chronic obstructive
		pulmonary disease.
		- In univariate analysis, the odds of mortality (95% CI) among those with malignancy was 6.36 (4.80 to 8.44).
	O'Brien 2020 (b)	- Of 9,525 deaths due to COVID-19 in Quebec and Ontario between March and July 2020, 1.8% had cancer as
		an associated cause.
Pre-existing chronic cond	ditions	
Mortality	Fisman 2020 (a)	- In multivariate regression analysis, chronic obstructive pulmonary disease (aOR 3.26, 95% CI 1.15-9.26) and
(people with COVID-19)		diabetes (aOR 2.19, 95% CI 1.08-4.42) were associated with increased mortality. Renal disease may be
		associated with increased mortality (aOR 2.37, 95% CI 0.97 to 5.77) but the confidence interval was wide.
		<ul> <li>Multivariate model controlled for age, immune compromise, and long-term care residency (as well as other</li> </ul>
		variables in model, described above)
	O'Brien 2020 (b)	<ul> <li>Among deaths from COVID-19, comorbidities listed on the death certificate have included dementia or</li> </ul>
		Alzheimer's disease were listed on the death certificate of 42% of females and 33% of males; other
		conditions listed included pneumonia (33%), hypertension (15%), ischemic heart disease (13%), respiratory

Outcome	Study	Key findings
(population)		
		failure (13%), renal failure (12%), diabetes (12%), chronic lower respiratory disease (10%), nervous system disorders excluding Alzheimer's disease (8%), and cancer (8%).
Pregnancy		
Hospitalization	Money 2021	- Compared to non-pregnant females of childbearing age, the unadjusted risk ratio (95% CI) for hospitalization
(people with COVID-19)		was 5.33 (4.51-6.20).
ICU admission	Money 2021	- Compared to non-pregnant females of childbearing age, the unadjusted risk ratio (95% CI) for ICU admission
(people with COVID-19)		was 5.88 (3.80-8.22).
Children and young adul	ts	
Mortality	O'Brien 2020 (b)	<ul> <li>Healthy young adults (&lt;45 years), adolescents, and children have been least likely to develop severe</li> </ul>
(people with COVID-19)		complications, including death; 100% of deaths from COVID-19 in these age groups as of July 31, 2020 had at
		least one comorbidity.
Hospitalization	Panetta 2020	- Of 10 infants hospitalized, 2 (20%) had chronic conditions, 5 (50%) were male
(people with COVID-19)		
Severe disease	Panetta 2020	- Among 27 infants with COVID-19, there was no significant difference in clinical manifestations by age (older
(people with COVID-19)		vs. younger infants)

aOR=adjusted odds ratio; Cl=confidence interval; COVID-19=novel coronavirus 2019; IRR=incidence rate ratio; OR=odds ratio; PHAC=Public Health Agency of Canada; RR=risk ratio; SET=Surveillance and Epidemiology Team

### **Appendix 3.** Characteristics of included studies

### A. Characteristics of studies contributing multivariate-adjusted associations for the main analysis, n=124

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Adrish, 2020 [1] USA (BronxCare Health System) Retrospective cohort NR 9 March to 18 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=1,173 Median (IQR), smokers: 64.0 (54.0-73.0) Median (IQR), non-smokers: 62.0 (52.0-73.0) 61.4%	RT-PCR; Electronic health records	Age, sex, and systemic steroids (as well as LDH levels)	Mortality (in-hospital)
Ahlström, 2021 [2] Sweden Retrospective cohort Non-industry 6 March to 27 May 2020; 27 May 2020	People with severe COVID- 19 N=1,981 Median (IQR): 61.0 (52-69) 74.0%	RT-PCR; Electronic health records	Age, sex, use of immunosuppressants, ischemic heart disease, non-ischemic heart disease, hypertension, type 1 diabetes, type 2 diabetes, stroke, chronic renal failure, chronic obstructive pulmonary disease, asthma, obesity, systemic inflammatory disease, solid organ transplant, cancer (as well as treatments for COVID-19)	Mortality
Alkhouli, 2020 [3] Multi-country (30 countries, 36% USA, 64% NR) Retrospective cohort Non-industry 20 January to 20 April 2020 (follow-up NR)	People with COVID-19 N=14,712 52.8 (17.9) 43.4%	Lab-confirmed; Electronic health records (TriNetX multinational research database)	Age, race, obesity, chronic obstructive lung disease, diabetes, heart failure, hypertension, stroke history, and nicotine dependence	Mortality
Altschul, 2020 [4] USA (New York City; Montefiore Medical Center) Retrospective cohort NR 1 March to 16 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=2,355 65.3 (15.9) 46.5%	RT-PCR; Electronic health records	Age, sex, congestive heart failure (as well as admission labs and clinical signs)	Mortality (in-hospital)
Alvarez-Garcia, 2020 [5]	Hospitalized with COVID-19 N=6,439 63.5 (18.0)	RT-PCR; Electronic health records	Age, sex, race, obesity, hypertension, diabetes, coronary artery disease, atrial fibrillation, chronic kidney disease, chronic obstructive	ICU admission Mechanical ventilation Mortality (in-hospital)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
USA (New York City; 5 Mount Sinai Healthcare System hospitals) Retrospective cohort NR 27 February to 26 June 2020; 18 July 2020	55.0%		pulmonary disease, previous treatment with RAASi	
An, 2020 [6] South Korea Prospective cohort NR 23 January to 2 April 2020; 16 April 2020	People with COVID-19 N=10,237 44.97 (19.79) 39.9%	Test positive; Korean National Health Insurance Service database	Age, sex, income level, residence, household type, disability (moderate or severe), chronic lung disease or asthma, diabetes, hyperlipidemia, cancer, cardiovascular disease, cerebrovascular disease, metformin use, cancer, hypertension (as well as presence of symptoms and infection route)	Mortality
Anantharaman, 2021 [7] USA (Northern California) Retrospective cohort NR 25 February to 8 June 2020; 45 days	People with COVID-19 N=4,627 74.5% 18-59 years; 13.5% 60-69 years; 11.1% 70+ years 48%	Unspecified lab test; Electronic medical records	Cancer history, age, sex, race/ethnicity, BMI, Charlson comorbidity index, hypertension, smoking, diabetes, neighbourhood deprivation index	Hospitalization ICU admission Mechanical ventilation Mortality
Anderson, 2020 [8] USA (New York City; NewYork-Presbyterian/ Columbia University Irving Medical Center & Allen Hospital) Retrospective cohort Non-industry 10 March to 24 April 2020; 10 June 2020	Hospitalized with COVID-19 People with severe COVID- 19 N=2,466 (152 mechanically ventilated) Median (IQR): 67.0 (54.0- 78.0) 58.0%	RT-PCR; Electronic health records (New-York- Presbyterian/Columbia University Irving Medical Center Clinical Data Warehouse; COVID-19 test results from Department of Health records)	Age, sex, race/ethnicity, smoking status, hypertension, diabetes, cancer, asthma, COPD, chronic kidney disease, pulmonary heart disease by BMI (stratified by age and sex)	Severe disease (in-hospital mortality or intubation) Mortality (among mechanically ventilated)
Attaway, 2020 [9] USA (Ohio & Florida) Retrospective cohort Non-industry 8 March to 13 May 2020 (follow-up NR)	People with COVID-19 Hospitalized with COVID-19 N=2,527 (705 hospitalized) 61.0 (15.5 47.8%	RT-PCR; Electronic health records (Cleveland Clinic COVID-19 registry)	Age, sex, BMI, cancer, coronary artery disease, diabetes mellitus, hypertension, immunosuppressive therapy and smoking status	Hospitalization ICU admission (among hospitalized) Mechanical ventilation (among hospitalized) Mortality (in-hospital)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Azar, 2020 [10] USA (Northern California) Retrospective cohort NR 1 January to 8 April 2020 (follow-up NR)	People with COVID-19 N=1,052 53.0 (95% CI, 51.8-54.1) 49.2%	Lab-confirmed; Electronic health records (Sutter Health)	Age, race/ethnicity, sex, insurance type, median income, homeless status, smoking status, Type 2 diabetes, hypertension, depression, congestive heart failure, cardiovascular disease, cancer, chronic obstructive pulmonary disease, asthma	Hospitalization
Bailey 2021 [11] USA (Pennsylvania, Ohio, Colorado, Delaware, Florida, Washington, Missouri) Retrospective cohort Non-industry 1 January to 8 September 2020 (follow-up NR)	Children with COVID-19 N=5,374 Age NR 48%	RT-PCR; Electronic health records	Race/ethnicity, age, presence of progressive condition, various types of conditions (endocrine, metabolic, malignancy), history of public insurance	Severe disease (pneumonia, sepsis, or respiratory failure)
Barron, 2020 [12] England Retrospective cohort No funding 1 March to 11 May 2020; 72 day observation period	General population N=61,414,470 (hospitalized NR) 78.6 (12.1) 61.5%	Antigen testing; National Data Repository (includes Master Patient Index, National Diabetes Audit, Bridges to Health national population segmentation & COVID patient notification system)	Age, sex, ethnicity, deprivation quintile, diabetes status	Mortality (in-hospital)
Bennett 2021 [13] Ireland Retrospective cohort Non-industry 2 March to 31 July 2020; to 14 September 2020, discharge or death	People with COVID-19 Hospitalized with COVID-19 N=19,789 (2,811 hospitalized) Age NR 43.6%	Nucleic acid testing; surveillance data and death certificates	Age, sex, chronic heart disease, chronic neurological conditions, chronic respiratory disease, chronic kidney disease, chronic liver disease, asthma (requiring medication), immunodeficiency including HIV, diabetes, BMI ≥kg/m² cancer/malignancy, other comorbidity, residential care facility	Hospitalization ICU admission Mortality
Berenguer, 2020 [14] Spain (nationwide) Retrospective cohort Non-industry NR to 17 March 2020; 17 April 2020	Hospitalized with COVID-19 N=4,035 Median (IQR): 70.0 (56.0- 80.0) 61.0%	RT-PCR; Electronic health records	Age, sex, cancer, chronic heart disease, chronic kidney disease stage 4, chronic neurological disorder, chronic pulmonary disease not asthma, dementia, diabetes, hypertension, liver cirrhosis, obesity (as well as admission signs and symptoms, vital signs, lab parameters)	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Bowe, 2020 [15] USA (Veteran Affairs Corporate Data Warehouse) Prospective cohort Non-industry 1 February to 23 July 2020; 30 July 2020	Hospitalized with COVID-19 N=5,216 veterans Median (IQR): 70.0 (61.0-76.0) 94.0%	RT-PCR; Electronic health records maintained by the Veteran Affairs Corporate Data Warehouse	Age, sex, race, BMI, smoking status, cardiovascular disease, type 2 diabetes, hypertension, immunosuppressants (as well as other medications, lab tests and vital signs)	Acute kidney injury Severe disease (acute kidney injury stage 3, acute kidney injury receiving kidney replacement therapy, and death)
Bravi, 2020 [16] Italy (Ferrara and Pescara provinces) Retrospective cohort No funding NR to 2 April or 24 April 2020 (by province); median 24 days	People with COVID-19 N=1,603 58.0 (20.9) 47.3%	RT-PCR; National database of pharmacological treatment linked with electronic health records	Age, sex, type 2 diabetes, hypertension, major cardiovascular diseases (heart failure, myocardial infarction, stroke), cancer, chronic obstructive pulmonary diseases (COPD, bronchitis, asthma, pneumonia, emphysema), renal disease	Hospitalization Severe disease (ICU admission or mortality composite)
Carter, 2020 [17] Italy & United Kingdom Prospective cohort No funding 27 February to 28 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=1,564 Median (IQR): 74.0 (61.0- 83.0) 57.7%	Lab-confirmed (95.1%), clinical diagnosis 64 (4.9%); Electronic and manual health records	Location of infection (community vs. nosocomial), age, sex, smoking status, diabetes, hypertension, coronary artery disease, reduced renal function, and clinical frailty scale (as well as CRP levels)	Hospital length of stay
Chan, 2020 [18] USA (New York, Mount Sinai Health System) Retrospective cohort No funding 27 February to 30 May 2020; 5 June 2020	Hospitalized with COVID-19 N=3,993 Median (IQR): 64.0 (56-78) 57.3%	RT-PCR; Electronic health records	Age, sex race, chronic kidney disease, congestive heart failure, diabetes mellitus, hypertension, liver disease, peripheral vascular disease (as well as lab values and vitals)	Acute kidney injury, stage 3
Chhiba, 2020 [19] USA (Chicago and surrounding suburbs) Retrospective cohort Non-industry 1 March to 15 April 2020; 30 April 2020	People with COVID-19 N=1,526 <40 y: 27.1% 40-69 y: 55.3% >70 y: 17.6% 47.0%	RT-PCR; Electronic health records (Northwestern Medicine Enterprise Data Warehouse)	Age, sex, race/ethnicity, smoking, obesity, CAD, diabetes, HTN, OSA, COPD, allergic rhinitis, rhinosinusitis, immunodeficiency	Hospitalization (with or without ICU admission)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Clift, 2020 [20] United Kingdom Retrospective cohort Non-industry 24 January to 30 June 2020; 28 days follow-up for mortality	General population N=8,256,158 NR NR	RT-PCR; Electronic health records (Qresearch primary care database linked to Public Health England testing results)	Age, sex, ethnicity, BMI, asthma, atrial fibrillation, blood cancer, cerebral palsy, chronic liver disease, COPD, congenital heart disease, coronary disease, dementia, diabetes Type 1, diabetes Type 2, epilepsy, heart failure, rare lung diseases (cystic fibrosis, extrinsic allergic alveolitis), severe mental illness, osteoporotic fracture, peripheral vascular disease, pulmonary hypertension or pulmonary fibrosis, previous stroke, rheumatoid arthritis or SLE, venous thromboembolism and treatments	Hospitalization Mortality
Cordtz 2020 [21] Denmark Prospective cohort Non-industry 1 March to 12 August 2020; to 12 August 2020	General population Hospitalized with COVID-19 N=4,597,229 (2,674 hospitalized) Median 49.8-71.2 years across groups 49.3%	Laboratory-confirmed; Danish national registers	Age, sex, inflammatory rheumatic diseases, cardiovascular disease, lung disease, diabetes mellitus, cancer	Hospitalization Severe disease (mechanical ventilation, acute respiratory distress syndrome, or death)
Cummings, 2020 [22] USA (2 hospitals in Northern Manhattan) Prospective cohort Non-industry 2 March to 1 April 2020; 14 April 2020	Hospitalized with COVID-19 N=1,150 Median (IQR): 62.0 (51.0-72.0) 66.0%	RT-PCR; Electronic health records	Age, sex, BMI, hypertension, chronic cardiovascular disease, COPD and/or interstitial lung disease, chronic kidney disease, diabetes (as well as symptom duration and vital signs)	Mortality (in-hospital)
Czernichow, 2020 [23] France (Paris) Retrospective cohort Non-industry 1 February to 30 April 2020; 30 May 2020	Hospitalized with COVID-19 N=5,795 59.8 (13.6) 65.4%	PCR; Electronic health records (EDS-COVID database)	Age, sex, BMI, cancer, chronic kidney disease, diabetes, dyslipidemia, heart failure, hypertension, sleep apnea, smoking status (stratified by age)	Mortality (in-hospital)
de Azambuja, 2020 [24] Belgium Prospective cohort Non-industry	Hospitalized with COVID-19 N=10,486 67.8 (17.0) 53.2%	PCR 91.6%, 7.6% CT-scan and clinical findings, and 0.8% unknown diagnostic method; Electronic health records (Sciensano -	Age, gender, RAAI use, cardiovascular disease, chronic kidney disease, chronic liver disease, chronic lung disease, chronic neurological disease, cognitive disorder, diabetes,	Severe disease (composite of ICU admission, invasive ventilation use and/or death within 30 days of COVID-19 diagnosis)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
15 February to 24 May 2020; followed 30 days for mortality		Belgian public health surveillance database)	haematological cancer, hypertension, immunosuppression including HIV	Mechanical ventilation Mortality (in-hospital)
Dennis, 2020 [25] United Kingdom Retrospective cohort Non-industry 1 March to 27 July 2020; followed up to 30 days	Hospitalized with COVID-19 and requiring HDU or ICU admission N=19,256 67.0 (16.9) 60.1%	RT-PCR (91% with swab positive result); Electronic health records	Age, sex, ethnicity, obesity, comorbidities	Mortality (in-hospital)
Denova-Gutiérrez [26] Mexico Retrospective cohort No funding 27 February to 10 April 2020 (follow-up NR)	People with COVID-19 N=3,844 45.4 (15.8) 58.0%	RT-PCR; Electronic health records (National Epidemiological Surveillance System)	Age, sex, smoking status, history of chronic diseases (cardiovascular disease, chronic kidney disease, immunosuppression), place of care, respiratory medical unit, and drug treatment, hypertension, obesity	Severe disease (pneumonia and other organ failure requiring treatment in ICU)
Docherty, 2020 [27] United Kingdom Prospective cohort Non-industry 6 February to 19 April 2020; minimum 2 week follow-up	Hospitalized with COVID-19 N=21,033 Median (IQR): 73.0 (58.0- 82.0) 59.9%	RT-PCR; routine health records	Age, sex, chronic cardiac disease, chronic pulmonary disease, diabetes, obesity, chronic neurological disorder, dementia, malignancy, moderate/severe liver disease	ICU admission Mortality
D'Silva 2020 [28] USA (nationwide) Retrospective cohort Non-industry 20 January to 15 August 2020; 30 days	People with COVID-19 N=4,748 58 (16) 21%	RT-PCR; Electronic health records (TriNetX)	Systemic autoimmune rheumatic diseases, age, sex, BMI, race/ethnicity, comorbidities, prior hospitalization	Hospitalization ICU admission Mechanical ventilation Acute renal failure Ischemic stroke Severe disease (composite ICU admission, mechanical ventilation, death) Mortality
Ellington, 2020 [29] USA (nationwide) Prospective cohort NR	Women with COVID-19 N=91,412 Pregnant: 25-34 y: 54.4%	Lab-confirmed or antigen test; CDC database from national COVID-19 surveillance	Age, ethnicity, underlying conditions	Hospitalization

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
22 January to 7 June 2020 (follow-up NR)	35-44 y: 22.1% Non-pregnant: 25-34 y: 38.2% 35-44 y: 38.3% 0% (all female)			
Esme, 2020 [30] Turkey Retrospective cohort NR 11 March to 27 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=16,942 60-64 y: 27.0% 65-69 y: 22.0% 70-74 y: 19.0% 75-79 y: 13.0% ≥80 y: 19.0% 49.0%	RT-PCR; Turkish Ministry of Health database	Sex, hypertension, diabetes, heart failure, chronic kidney disease. Dementia, cancer (stratified by age)	Mortality (in-hospital)
Floyd 2021 [31] USA (Philadelphia, PA) Retrospective cohort Non-industry 17 March to 26 August 2020 (follow-up NR	Children with COVID-19 N=979 28% 0-4 years, 23% 5-11 years, 34% 12-17 years, 15% 18-21 years 51%	RT-PCT; Electronic health recrods	Current asthma (based on EHR registry definition; diagnosis or treatment in past year, persistent asthma); age, sex, race, ethnicity, obesity, number of chronic conditions	Hospitalization
Fond, 2020 [32] France (nationwide) Retrospective cohort  NR 1 February 2020 to 9 June 2020 (follow-up NR)	Hospitalized with COVID-19 N=50,750 Median (IQR): 71.0 (57.0- 83.0) 56.8%	ICD-10 codes for lab- confirmed COVID; French national hospital database	Age, sex, social deprivation, schizophrenia, smoking status, overweight and obesity, Charlson Comorbidity Index score (stratified by age)	ICU admission Mortality (in-hospital)
Fresan, 2020 [33] Spain (Navarra region) Prospective cohort Non-industry 1 March to 30 April 2020; followed 30 days for mortality	People with COVID-19 Hospitalized with COVID-19 N=433,995 (1,105 hospitalized) NR 50.0%	RT-PCR and rapid antibody testing; Regional health service electronic records	Age, sex, country of origin, municipality size, annual taxable income level, primary health care visits in prior 12 months, hospitalization in prior 12 months, smoking status, hypertension, and major chronic conditions (stratified by age, and sex)	Hospitalization Severe disease (ICU admission or mortality composite among hospitalized)
Garazzino, 2021 [34] Italy (nationwide) Retrospective cohort	Children with COVID-19 N=759 Mean (IQR): 7.3 (1.4-12.4)	RT-PCR or antibody tests; health records	Age, sex, chronic comorbidities, immunosuppression (as well as more than one infected family member, symptoms)	Hospitalization Mechanical ventilation ICU admission

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
NR Up to 15 September 2020; at least 2 weeks	56.1%			Severe disease (pneumonia, severe acute respiratory illness, acute respiratory distress syndrome, neurological disturbances, severe dehydration requiring intravenous rehydration, severe bacterial suprainfection, specific involvement of a single organ/apparatus requiring hospitalization, multisystem inflammatory syndrome)
Geretti, 2020 [35] United Kingdom (England, Scotland, Wales) Prospective cohort Non-industry 17 January to 18 June 2020; followed 28 days for mortality	Hospitalized with COVID-19 N=47,592 Median (IQR) HIV +ve: 56.0 (49.0-62.0) HIV -ve: 74.0 (60.0-84.0) 57.3%	RT-PCR (90.5%); Electronic health records (ISARIC WHO CCP-UK)	Age, sex, ethnicity, obesity, chronic cardiac disease, chronic haematological disease, chronic neurological disease, chronic pulmonary disease, chronic renal disease, dementia, diabetes, liver disease & malignancy (as well as hospital admission date & indeterminate/probable hospital acquisition of COVID-19)	ICU admission Mortality
Giannouchos, 2020 [36] Mexico Retrospective cohort No funding NR (dataset released 31 May 2020)	People with COVID-19 Hospitalized with COVID-19 N=89,756 (31,271 hospitalized) 46.2 (16.0) 56.4%	RT-PCR; Mexican Health Ministry	Age, gender, nationality (Mexican/ not), number of comorbidities, smoking status	Hospitalization Severe disease (intubation, ICU admission or mortality composite among hospitalized)
Giorgi Rossi, 2020 [37] Italy (Reggio Emilia province) Prospective cohort Non-industry 27 February to 2 April 2020; 3 April 2020	People with COVID-19 N=2,653 <51 y: 696 51-60 y: 528 61-70 y: 413 71-80 y: 420 ≥81 y: 596 50.1%	PCR; SARS-CoV-2 special database (Province of Reggio Emilia, Italy) and electronic health records	Age, sex, Charlson Index, place of residence (as well as calendar period & time from symptom to diagnosis)	Hospitalization Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Gottlieb, 2020 [38] USA (Rush University Medical Center, Chicago) Retrospective cohort NR 4 March to 21 June 2020 (follow-up NR)	People with COVID-19 Hospitalized with COVID-19 N=8,673 (1,483 hospitalized) Median (IQR): 41.0 (29.0- 54.0) 46.6%	Lab-confirmed; Electronic health records	Age, sex, race, ethnicity, tobacco use, asthma, COPD, hypertension, hyperlipidemia, diabetes, prior cerebrovascular event (stroke), coronary artery disease, congestive heart failure, chronic kidney disease, current end-stage renal disease, cirrhosis, obstructive sleep apnea, bloodborne cancer, solid organ cancer, HIV, solid organ transplant, BMI	Hospitalization ICU admission (among hospitalized)
Gotzinger, 2020 [39] Europe (21 countries, 77 healthcare institutions) Retrospective cohort Non-industry 1 April to 24 April 2020 (follow-up NR)	People with COVID-19 N=582 Median (IQR): 5.0 (0.5-12.0) 53.0%	RT-PCR; Electronic health records (Pediatric Tuberculosis Network European Trials Group)	Age, sex, pre-existing medical conditions (as well as signs or symptoms)	ICU admission
Grasselli, 2020 [40] Italy (Lombardy) Retrospective cohort Non-industry 20 February to 22 April 2020; 30 May 2020	People with severe COVID- 19) N=3,988 Median (IQR): 63.0 (56.0- 69.0) 80.0%	RT-PCR; Regional Health System Database	Age, sex, pre-existing comorbidities, (as well as clinical findings & medications)	Mortality (in-hospital & in-ICU)
Guerrero-Torres, 2020 [41] Mexico Retrospective cohort NR 27 February to 31 August (follow-up NR)	Hospitalized with COVID-19 N=25,771 57.4 (15.7) 63.2%	PCR; Electronic health records (National Epidemiological Surveillance System)	Age, sex, comorbidities, smoking status, state of residence, type of care institution (as well as time from onset of symptoms to first evaluation)	Mortality
Gupta, 2020 (a) [42] USA (65 hospitals across the country) Prospective cohort NR 4 March to 4 April 2020; median follow-up 16 days (IQR 8-28 days)	People with severe COVID- 19 N=2,215 60.5 (14.5) 64.8%	Lab-confirmed; Electronic health records	Age, sex, race, hypertension, diabetes, BMI, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, current smoking status, active cancer (as well as lab values assessed at ICU admission)	Mortality Mortality (among mechanically ventilated on day 1 of ICU admission)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Gupta, 2020 (b) [43] USA Prospective cohort No funding 4 March to 11 April 2020; 1 August 2020	People with severe COVID- 19 N=3,099 (637 with acute kidney injury) Median (IQR): 62.0 (51.0- 71.0) 64.6%	Lab-confirmed; Electronic health records (STOP-COVID database)	Age, sex, race, comorbidities, (as well as days from hospital to ICU admission, illness severity on admission, lab values, secondary infection on day 1, altered mental status on day 1, shock, hospital size, regional density of COVID-19-quartiles by county)	Acute kidney injury Mortality (among ICU admitted and with acute kidney injury)
Hajifathalian, 2020 [44]  USA (1 hospital in Manhattan, New York City) Retrospective cohort NR 4 March to 9 April 2020 (follow-up NR)	People with COVID-19 N=1,059 (768 hospitalized) 61.1 (18.3) 58.0%	RT-PCR; Medical records	Age, sex, race/ ethnicity, BMI, pre-existing comorbidities (as well as vital signs)	Severe disease (ICU admission/mortality composite)
Hamer, 2020 (a) [45] England (UK Biobank) Prospective cohort Non-industry 16 March to 26 April 2020; 26 April 2020	General population N=387,109 56.2 (8.0) 44.9%	RT-PCR; UK-Biobank, includes self- report of risk factors	Age, sex, education, ethnicity, diabetes, hypertension, cardiovascular disease (heart attack, angina, or stroke), lifestyle score, smoking, physical activity, alcohol consumption, BMI category	Hospitalization
Hamer, 2020 (b) [46] England (UK Biobank) Retrospective cohort No funding 16 March to 26 April 2020 (follow-up NR)	General population N=334,329 56.4 (8.1) 45.5%	RT-PCR; UK Biobank Study (clinic visit; self-report); Public Health England	Age, sex, smoking status, physical activity, alcohol use, ethnicity, education, diabetes, cardiovascular disease (heart attack, angina, or stroke), hypertension, BMI	Hospitalization
Harrison, 2020 [47] USA Retrospective cohort No funding 20 January to 26 May 2020; median follow-up 54 days (IQR 36-68)	People with COVID-19 N=31,461 Median (IQR): 50.0 (35.0-63.0) 45.5%	Lab-confirmed plus ICD-10 codes; Electronic health records (TriNetX network)	Age, sex, ethnicity, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, liver disease (mild, moderate, severe), diabetes, hemiplegia/paraplegia, renal disease, any malignancy, metastatic solid tumor, AIDS/HIV	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Hernandez-Vasquez, 2020 [48] Mexico Retrospective cohort No funding Through 18 May 2020 (follow-up NR)	Patients with COVID-19 N=51,053 46.6 (15.8) 57.6%	RT-PCR; Secretaría de Salud de México (national epidemiologic surveillance database)	Age, sex, smoking status (stratified by sex)	Mortality
Hirsch, 2020 [49] USA (New York City, Northwell health) Retrospective cohort NR  1 March to 5 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=5,449 Median (IQR): 64.0 (52.0-75.0) 60.9%	RT-PCR; Heath records (managed by Sunrise Clinical Manager)	Age, sex, race, diabetes, hypertension, cardiovascular disease, obesity, HIV, cancer, ACE-I or ARB use (as well as tertiary hospital, mechanical ventilation and medications)	Acute kidney injury
Huh, 2020 [50] South Korea Retrospective cohort Non-industry NR	People with COVID-19 N=2,231 7.3% 20-29, 10.4% 30-39, 17.1% 40-49, 30.3% 50-59, 22.3% 60-69, 9.5% 70-79, 3.0% ≥80  Hospitalized with COVID-19	RT-PCR; Electronic health records (National Health Insurance Service database, and Korea Centers for Disease Control and Prevention COVID-19 registry)  RT-PCR; Hospital charts	Age, sex, Charlson comorbidity index, BMI, asthma, cancer, chronic heart disease, chronic kidney disease, chronic liver disease, chronic lung disease, diabetes, hypertension, rheumatologic disease, chronic rheumatologic disease, coverage for low income  Age, sex, comorbidities (as well as medications)	Severe disease (supplementary oxygen, high-flow nasal cannula, non-invasive ventilation, mechanical ventilation, extracorporeal membrane oxygenation, or mortality)  Mortality (in-hospital)
Italy (nationwide) Retrospective cohort Non-industry 9 March to 9 April 2020 (follow-up NR)	N=1,591 66.5 (0.4) 64.0%	N T City Hospital chares	rige, sex, comorbialites (as well as medications)	Mortality (in nospital)
Ioannou, 2020 [52] USA Prospective cohort Non-industry 28 February to 14 May; 22 June 2020	People with COVID-19 N=10,131 63.6 (16.2) 91.0%	RT-PCR; US Veterans Health Administration database	Age, sex, race, ethnicity, location (urban vs. rural), Charlson comorbidity index, asthma, BMI, cancer, cerebrovascular disease, chronic kidney disease, COPD, cirrhosis, coronary heart failure, diabetes, dialysis, hyperlipidemia, hypertension, obesity hypoventilation, obstructive sleep apnea, alcohol dependence,	Hospitalization ICU admission Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
			smoking status (as well as COVID-19 related deaths per million residents)	
Izurieta, 2021 [53] USA (Medicare beneficiaries) Retrospective cohort Non-industry 1 April 2020 to 8 May 2020; at least 21 days	General population (all over 65 years) N=2,533,329 Median 73.0 44.4%	RT-PCR; Electronic medical records	Chronic conditions, social factors (deprivation index), frailty, immunocompromise (immunocompromising conditions or use of immunosuppressive drugs) (as well as influenza vaccination)	Hospitalization Mortality
Izzy, 2020 [54] USA (Massachusetts) Prospective cohort NR 1 February to 14 April 2020; 25 April 2020	People with COVID-19 N=5,190 (1,489 hospitalized) Median (IQR): 52.0 (36.0- 66.0) 46.0%	Nucleic acid testing; Electronic health records maintained by Mass General Brigham	Age, sex, smoking status, BMI, diabetes, hyperlipidemia, hypertension, obstructive lung disease, interstitial lung disease, coronary artery disease, congestive heart failure, cerebrovascular disease, obstructive sleep apnea, chronic kidney disease, transplantation, autoimmune disease, malignancy (stratified by ethnicity, and sensitivity analysis with median household income)	Hospitalization ICU admission (among hospitalized)
Jakob, 2020 [55] Europe (112 LEOSS partner sites, 98.1% Germany) Retrospective cohort No funding 16 March to 14 May 2020 (follow-up NR)	People with COVID-19 (92.7% recruited from hospitals) N=2,155 ≤14 years: 1.2% 15-25 years: 2.7% 26-45 years: 14.7% 46-65 years: 34.4% 66-85 years: 39.6% >85 years: 7.4% 59.7%	RT-PCR; data from the Lean European Open Survey on SARS-CoV-2- Infected Patients (LEOSS) cohort study	Age, sex, cardiovascular disease, diabetes, pulmonary disease	Severe disease (oxygen supplementation, mechanical ventilation, clinically meaningful increase of prior oxygen home therapy, new cardiac arrhythmia, new pericardial effusion >1cm, new heart failure with pulmonary edema, congestive hepatopathy or peripheral edema, need for catecholamines, qSOFA ≥2, acute renal failure in need of dialysis, liver failure with Quick < 50%, composite)
Ji, 2020 [56] South Korea Retrospective cohort	People with COVID-19 N=7,341 47.1 (19.0)	RT-PCR; HIRA insurance claims database and	Age, sex, residence, Charlson comorbidity index, healthcare utilization, comorbidities	Severe disease (oxygen therapy, mechanical ventilation, extracorporeal

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Non-industry NR to 15 May 2020 (follow- up NR)	40.5%	Korean Center for Disease Control database		membrane oxygenation, and cardiopulmonary resuscitation)
Jiminez, 2020 [57] Spain (Madrid) Retrospective cohort No funding 1 March to 28 May 2020; 28 May 2020	Hospitalized with COVID-19 N=1,549 Median (IQR): 69.0 55.0- 81.0 57.5%	RT-PCR; Electronic health records	Age, sex, migrant status, cardiovascular disease, hypertension, diabetes, smoking status, COPD, OSAS, neurological disease, chronic kidney disease, cancer (as well as biomarkers & clinical features on presentation)	Mortality (in-hospital)
Kabarriti, 2020 [58] USA (New York City) Retrospective cohort NR 14 March to 15 April 2020; 27 April 2020	People with COVID-19 N=5,902 Median (IQR): 58.0 (44.0-71.0) 46.0%	RT-PCR; Electronic health records (Bronx Montefiore Health System)	Age, sex, race/ethnicity, SES, BMI, cancer, cardiovascular disease, chronic pulmonary disease, dementia, diabetes, hemiplegia or paraplegia, HIV/AIDS, hypertension, kidney disease, liver disease, peptic ulcer	Mortality
Kaeuffer, 2020 [59] France (Strasbourg and Mulhouse) Prospective cohort Non-industry March 2020; up to day 7 following hospitalization	Hospitalized with COVID-19 N=1,045 66.3 (16.0) 58.6%	RT-PCR; Electronic medical records	Age, sex, body mass index, hypertension, diabetes, chronic lung disease, immunosuppression, chronic kidney disease (as well as symptoms, biological findings)	Severe disease (ICU admission or mortality) Mortality
Kim, 2020 (a) [60] USA (154 acute-care hospitals in 74 counties in 13 states) Retrospective cohort Non-industry 1 March to 2 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=2,491 Median (IQR): 62.0 (50.0- 75.0) 53.2%	Lab-confirmed; Laboratory and reportable condition databases, hospital infection control databases, electronic medical records, and/or reviews of hospital discharge records	Age, sex, race and ethnicity, current or former smoker; a history of hypertension, obesity, diabetes, chronic lung disease, cardiovascular disease, neurologic disorders, renal disease, immunosuppression, hematologic conditions, rheumatologic/autoimmune conditions (as well as angiotensin receptor blocker use prior to hospitalization)	ICU admission Mortality (in-hospital)
Kim, 2020 (b) [61] USA (New York City, Northwell health system) Retrospective cohort Non-industry	Hospitalized with COVID-19 N=10,861 Median (IQR): 65.0 (54.0-77.0) 59.6%	PCR; Electronic health records (Northwell Health System)	Age, sex, race/ethnicity, BMI, asthma, cancer, chronic kidney disease, COPD, coronary artery disease, diabetes mellitus, end stage renal disease, hypertension, smoking status, hospital type	Mechanical ventilation Mortality (in-hospital)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
1 March to 27 April 2020; 12 May 2020				
King, 2020 [62] USA Prospective cohort Non-industry 2 March to 18 July 2020; 19 August 2020	People with COVID-19 N=3,681 Median (IQR): 64.8 (53.7-73.4) 92.6%	Lab-confirmed; US Veterans Health Administration database	Age, sex, race/ethnicity, Charlson comorbidity index, AIDS, asthma, cancer, metastatic cancer, cerebrovascular accident, chronic pulmonary disease, dementia, diabetes (without or with complications), hypertension, liver disease (mild, severe), myocardial infarction, peptic ulcer disease, peripheral vascular disease, plegia, renal disease, rheumatological disease	Mortality
Kjeldsen, 2021 [63] Denmark Retrospective cohort Industry and non-industry 1 March to 31 October 2020 (follow-up NR)	Hospitalized with COVID-19 N=2,943 Median (IQR): Exposed 74.0 (63-80) Controls 69.0 (54-80) 55.6%	RT-PCR; Electronic medical records	Age, sex, Charlson comorbidity index, chronic inflammatory diseases	Mechanical ventilation Mortality
Klang, 2020 [64] USA (New York City, 5 Mount Sinai hospital campuses) Retrospective cohort 1 March to 17 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=3,406 Median age (IQR) Survivors Age >50 y: 68.0 (60.0-77.0) Age ≤50 y: 40.0 (34.0-46.0) Non-survivors Age >50 y: 76.0 (67.0-84.0) Age ≤50 y: 46.5 (42.8-49.0) 57.6%	PCR; Electronic health records (5 campus hospitals in New York City)	Age, sex, coronary artery disease, congestive heart failure, hypertension, diabetes, hyperlipidemia, chronic kidney disease, cancer, smoking, BMI, race (stratified by age)	Mechanical ventilation Mortality (in-hospital)
Ko, 2020 [65] USA Prospective cohort Non-industry 1 March to 23 June 2020; 23 June 2020	General population N=5,416 Median (IQR): 55.0 (42.0-67.0) 53.0%	Lab-confirmed; COVID-19–Associated Hospitalization Surveillance Network (COVID-NET)	Age, sex, race/ethnicity	Hospitalization
Kohl, 2020 [66] United Kingdom (2 hospitals, Derby) Retrospective cohort	Hospitalized with COVID-19 N=1,161 72.1 (16.1) 56.6%	RT-PCR; Electronic health records	Age, sex, ethnicity, cancer, cerebrovascular disease, chronic kidney disease, chronic liver disease, chronic lung disease, congestive cardiac failure, dementia, diabetes with	Acute kidney injury Mortality (in-hospital)

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
No funding 5 March to 12 May 2020 (follow-up NR) Kragholm, 2020 [67] Denmark (nationwide) Retrospective cohort End of February to 16 May 2020; followed up to 30	People with COVID-19 N=4,842 Median (IQR) Males: 57.0 (42.0-73.0) Females: 52.0 (38.0-71.0)	RT-PCR; Danish National Patient Registry, Danish Civil Registration System and Danish Prescription Registry	complications, myocardial infarction, paraplegia, peripheral vascular disease, care home residence (as well as treatments)  Age, alcohol use, obesity, hypertension, diabetes, chronic obstructive pulmonary disease, sleep apnea, prior myocardial infarction, chronic ischemic heart disease, heart failure, atrial fibrillation or flutter, stroke,	Severe disease (severe COVID- 19, ICU admission or mortality composite) ICU admission Mortality
days	47.1%		peripheral artery disease, liver disease, rheumatic disease, chronic kidney disease, cancer (stratified by sex)	
Kummer, 2020 [68] USA (New York City, 5 Mount Sinai hospital campuses) Retrospective cohort No funding 1 March to 1 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=3,248 Median (IQR) History of stroke: 75.0 (65.0-83.0) No history of stroke: 66.0 (55.0-77.0) 58.2%	PCR; Electronic health records (5 hospital campuses across Mount Sinai health system)	Age, sex, hypertension, coronary artery disease, diabetes, dyslipidemia, congestive heart failure, atrial fibrillation, chronic kidney disease, obesity, COPD, asthma, active smoking, malignancy, stroke	Mortality (in-hospital)
Kundi, 2020 [69] Turkey (nationwide) Retrospective cohort Non-industry 11 March to 22 June 2020; 20 July 2020	Hospitalized with COVID-19 N=18,234 74.1 (7.4) 46.6%	RT-PCR; Electronic health records (e-Pulse and National Healthcare Information System of Turkey)	Age, sex, coronary artery disease, coronary artery bypass graft, congestive heart failure, valvular heart disease, hypertension, peripheral vascular disease, cerebrovascular disease, COPD, diabetes, liver disease, renal failure, iron deficiency anemia, rheumatoid disease, peptic ulcer disease, depression, cancer, substance abuse, alcohol abuse, acquired immunodeficiency syndrome, hospital frailty risk score	Hospital stay (>10 days) ICU admission Mechanical ventilation Mortality
Lassale, 2020 [70] United Kingdom Retrospective cohort No funding 16 March to 26 April 2020 (follow-up NR)	People with COVID-19 N=340,966 56.2 (NR) 46.0%	RT-PCR; UK Biobank	Age, sex, ethnicity, education, townsend score, physical activity, smoking, alcohol use, BMI, household size, hypertension, cardiovascular disease, chronic bronchitis, ever seen psychiatrist (as well as lab values)	Hospitalization

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Lee, 2020 (a) [71] South Korea Retrospective cohort Non-industry 1 January to 15 May 2020 (follow-up NR)	People with COVID-19 N=2,640 Mental illness: 57.8 (16.8) No mental illness: 58.3 (16.6) 39.1%	RT-PCR; South Korean national health insurance claims database	Mental illness, age, sex, region of residence, diabetes, cardiovascular disease, cerebrovascular disease, COPD, asthma, hypertension, chronic kidney disease, Charlson comorbidity index	Severe disease (ICU admission, mechanical ventilation or mortality composite) Mortality
Lee, 2020 (b) [72] South Korea Retrospective cohort Non-industry NR to 15 May 2020; 15 May 2020	People with COVID-19 N=7,339 47.1 (19.0) 40.1%	RT-PCR; Korean Health Insurance Claim Data (98% of population)	Age, sex, location, influenza, tuberculosis, COPD, pneumonia, asthma, diabetes, chronic kidney disease, liver disease, hypertension, cardiovascular disease, malignancy, HIV (as well as treatments and medications)	Severe disease (oxygen therapy, mechanical ventilation, CPR, or extracorporeal membrane oxygenation) Mortality
Lee, 2020 (c) [73] South Korea (Daegu) Retrospective cohort Non-industry NR to 8 March 2020 (follow-up NR)	People with COVID-19 People with severe COVID- 19 N=4,742 41.8 (19.0) 45.5%	RT-PCR; Health Insurance Review & Assessment Service database	Age, sex, insurance type, facility location, malignancy, COPD, ischemic heart disease, hypertension, diabetes	ICU admission Mechanical ventilation (among ICU admitted)
Leon-Abarca, 2020 [74] Mexico Retrospective cohort NR NR	General population (children) N=21,161 NR NR	RT-PCR; Electronic health records (Mexican Open Registry)	Age, sex, area of residence, immunodeficiencies, asthma, obesity, cardiovascular diseases, chronic kidney disease, hypertension, diabetes	Hospitalization ICU admission Mortality
Loffi, 2020 [75] Italy (Lombardy) Retrospective cohort No funding 21 February to 31 March 2020; 4 May 2020	Hospitalized with COVID-19 N=1,252 64.7 (15.5) 63.7%	RT-PCR; Electronic health records; telephone follow up for discharged patients	Coronary artery disease, age, sex, smoking status, hypertension, hyperlipidemia, diabetes, chronic kidney disease, prior cerebrovascular event, atrial fibrillation (as well as left ventricular ejection fraction <35%)	Mortality
Ludvigsson, 2021 [76] Sweden Prospective cohort Non-industry 1 Febrary to 31 July 2020 (to 31 July 2020 or death)	People with COVID-19 Hospitalized with COVID-19 N=365,202 (679 hospitalized) 52.7 (16.9) 51%	RT-PCR (based on ICD codes)	Age, sex, country, calendar period, education, country of birth, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, end-stage renal disease, liver disease with alcohol use disorder, obesity or dyslipidemia, obstructive sleep apnea, cancer, psychiatric disease	Hospitalization Severe disease (ICU admission or death) ICU admission Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Lunski, 2020 [77] USA (Louisiana) Retrospective cohort No funding 1 March to 30 April 2020 (follow-up NR)	People with COVID-19 N=5,145 <65 y: 74.0% ≥65 y: 26.0% 390%	PCR; Electronic health records (Ochsner's Epic)	Age, sex, race, cancer, chronic kidney disease, COPD, coronary artery disease, diabetes, hypertension, obesity, smoking status (as well as vitals and lab values)	Mortality
Mallow, 2020 [78] USA (276 hospitals across USA) Retrospective cohort No funding 15 March to 30 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=21,676 64.9 (17.2) 52.8%	Lab-confirmed; Electronic health records (ICD codes)	Age, CDC risk factors, sex, insurance type, chronic lung disease, moderate/severe asthma, heart condition, immunocompromised, obesity, diabetes, chronic kidney disease with dialysis, liver disease, hypertension (as well as statin use, DNR status, hospital status & hospital bed size)	Hospital length of stay ICU admission ICU length of stay Mortality (in-hospital)
Mancilla-Galindo, 2021 [79] Mexico Retrospective cohort No funding 28 February to 30 May 2020 (follow-up NR)	People with COVID-19 N=83,779 46.3 (15.9) 56.6%	RT-PCR; Federal Government of Mexico database	Age, sex, diabetes, chronic obstructive pulmonary disease, immunosuppression, hypertension, obesity, chronic kidney disease (as well as pneumonia)	Mortality
Martinez-Portilla, 2021 (a, b) [80, 81] Mexico	Women with COVID-19 N=262,749 (10,366 in matched sample) 32.9 (7.5) 0%	RT-PCR; Mexican National Registry database	Age, language, nationality, health insurance agency, chronic obstructive pulmonary disease, asthma, smoking, hypertension, cardiovascular disease, diabetes, obesity, chronic renal disease and immunosuppression	Mortality Severe disease (pneumonia) ICU admission Mechanical ventilation
Mikami, 2020 [82] USA (New York City, Mount Sinai network) Retrospective cohort NR 13 March to 17 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=3,708 (2,820 analyzed with an outcome) Median age (IQR) Survivors: 62.0 (49.0-73.0) Non-survivors: 76.0 (65.0-85.0) Survivors: 56.0% Non-survivors: 59.1%	RT-PCR; Electronic health records (Mount Sinai Health system, 8 hospitals and >400 ambulatory practices)	Age, sex, race, cigarette use history, hypertension, diabetes, cancer, azithromycin use, BMI (as well as treatments and lab values)	Mortality (in-hospital)
Miller, 2020 [83]	Hospitalized with COVID-19 N=2,316 Alive at 30 days: 62.0 (15.9)	RT-PCR; Electronic health records (Henry Ford Health System)	Age, sex, residence in low-income area, medicaid insurance, race, COPD, congestive heart failure, coronary artery disease, chronic	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
USA (metropolitan Detroit, southeast & south-central Michigan) Retrospective cohort Non-industry 7 March to 30 April 2020; followed for at least 30 days	Deceased at 30 days: 74.7 (13.8) Alive at 30 days: 50.5% Deceased at 30 days: 57.5%		kidney disease, hypertension, obesity, diabetes mellitus, cancer, dementia, peripheral vascular stroke, stroke	
Misra-Hebert, 2020 [84] USA (Ohio & Florida) Retrospective cohort Industry & Non-industry 8 March to 9 June 2020 (follow-up NR)	People with COVID-19 N=4,904 Median age (IQR) Healthcare worker: 40.6 (30.0-54.0) Non-healthcare worker: 54.5 (39.0-69.0) 48.5%	Test-positive; Electronic health records (COVID-19 Cleveland Clinic registry)	Age, sex, race, ethnicity, BMI, asthma, diabetes, hypertension, immunosuppressive disease, median income, population per housing unit, smoking history (as well as presenting symptoms, medications and lab values)	Hospitalization ICU admission
Molnar, 2020 [85] USA Prospective cohort NR 4 March to 8 May 2020; 5 June 2020	People with a COVID-19 ICU admission N=4,153 Median (IQR): 62.0 (52.0-71.0) 64.0%	Test-positive; Electronic medical records	Age; gender; race; ethnicity; pre-existing conditions; immunosuppression (solid organ transplantation at baseline); smoking status	Renal replacement therapy (for acute kidney injury) Mechanical ventilation Mortality
Moreira, 2021 [86] USA (nationwide) Prospective cohort Non-industry 2 March to 16 July 2020; at least 1 month	Children with COVID-19 N=27,045 (20,096 hospitalized) 30% 0-9 years, 70% 10-19 years 48%	Nasopharyngeal/throat swabs or serologic testing; CDC COVID-NET database	Age, sex, race/ethnicity, presence of comorbidities	Hospitalization Mortality (in hospital)
Murillo-Zamora, 2021 [87] Mexico (nationwide) Retrospective cohort No funding 4 March to 15 August 2020	Hospitalized with COVID-19 N=66,123 3.4% 20-29 years, 16.1% 30- 34 years, 33.9% 45-59 years, 46.6% 60+ years 60.7%	RT-PCR; Epidemiologic surveillance data	Immunosuppression (any cause except type 2 diabetes and chronic kidney disease), age, sex, tobacco use, obesity, asthma, COPD, type 2 diabetes, arterial hypertension, chronic kidney disease (as well as pneumonia at hospital admission)	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Nachtigall, 2020 [88] Germany (nationwide) Retrospective cohort Non-industry 12 February to 12 June 2020; longest follow-up was mean 17.21 days	Hospitalized with COVID-19 N=1,904 Median (IQR): 73.0 (57.0- 82.0) 51.5%	RT-PCR; Electronic health records (Helios network)	Age, sex, cardiovascular disease, diabetes, lung disease, malignancy	ICU admission Mechanical ventilation Mortality
Nair, 2020 [89] USA (Northwell Health Hospitals in New York) Retrospective cohort Non-industry 1 March to 27 April 2020; to 4 June 2020	Hospitalized with COVID-19 N=1,707 62.9 (11.6) 68.7%	RT-PCR; Electronic health records	Solid organ transplant, race/ethnicity, body mass index, age, sex, glomerular filtration rate, diabetes, hypertension, coronary artery disease, peripheral vascular disease/peripheral artery disease, heart failure, chronic obstructive pulmonary disease	Mechanical ventilation Acute kidney injury Severe disease (mechanical ventilation or death)
Nijman, 2020 [90] Netherlands (Gelderland and North-Brabant) Prospective cohort March to May 2020; follow-up NR	Hospitalized with COVID-19 N=1,006 Median (IQR): 69 (58-77) 63.9%	RT-PCR; Electronic health records	Age, sex, BMI, diabetes, cardiovascular disease (including hypertension), hypertension, pulmonary disease, immunocompromised (hematological malignancy, stem cell or organ transplant, auto-immune disease, HIV/AIDS, and/or use of immunosuppressive medication) (as well as chronic use of anticoagulant or antiplatelet medication, ACE inhibitors/ angiotensin II receptor blockers, chest x-ray, CT scan severity score, symptoms, lab values)	Mortality (in-hospital death or palliative discharge)
Ng, 2020 [91] USA (13 hospitals in a large New York Health system) Retrospective cohort NR 1 March to 27 April 2020; 27 May 2020	Hospitalized with COVID-19 N=10,482 Median (IQR): 66.0 (54.0-77.0) 59.5%	RT-PCR; Electronic health records	End-stage kidney disease requiring dialysis, age, sex, race/ethnicity, diabetes, hypertension, cardiovascular diseases (coronary artery disease, heart failure, peripheral vascular disease), respiratory diseases (asthma, COPD), chronic liver disease, cancer, BMI (as well as medication and mechanical ventilation)	Hospital length of stay Mechanical ventilation Mortality (in-hospital)
Parra-Bracamonte, 2020 (a, b) [92, 93] Mexico (475 monitoring units in nationwide)	People with COVID-19 N=331,298 (328,922 analyzed)	RT-PCR; Open data source of Epidemiologic Surveillance Source of Respiratory Viral Diseases	Age, sex, smoking habits, hypertension, obesity, diabetes, cardiopathy, COPD, asthma, immunosuppressed, chronic kidney disease, other complication	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Retrospective cohort NR 13 January to 17 July 2020 (follow-up NR)	Median (IQR): 44.0 (33.0-56.0) 53.8%			
Patel, 2020 [94] England (UK Biobank) Retrospective cohort Non-industry 16 March to 14 April 2020 (follow-up NR)	General population N=418,794 65.8 (NR) 45.0%	RT-PCR; UK Biobank study	Age, sex, race, region, coronary artery disease, hypertension, diabetes, heart failure, ischemic stroke, BMI, COPD, prior pneumonia, Alzheimer's disease/dementia, chronic kidney disease, smoking status, statin use, alcohol consumption, Townsend Index, average income	Hospitalization
Petermann-Rocha, 2020 [95] England Prospective cohort Non-industry 16 March to 28 June 2020; 28 June 2020	General population N=383,845 67.3 (8.1) 55.1%	RT-PCR; UK Biobank, Hospital Episode Statistics and national mortality registers (includes self- report of risk factors)	Age, sex, deprivation index, ethnicity, frailty	Hospitalization
Petrilli, 2020 [96] USA (New York City & Long Island) Prospective cohort Non-industry 1 March to 8 April 2020; 5 May 2020	People with COVID-19 Hospitalized with COVID-19 N=5,279 (2,741 hospitalized) Median (IQR): 54.0 (38.0- 66.0) 49.5%	RT-PCR; Electronic health records	Age, sex, race/ethnicity, history of hypertension, hyperlipidemia, coronary artery disease, heart failure, pulmonary disease (COPD or asthma), malignancy (excluding nonmetastatic non-melanoma skin cancer), diabetes, obesity	Hospitalization Severe disease (ICU admission, mechanical ventilation, discharge to hospice or mortality composite, among hospitalized) Mortality (in-hospital or at discharge to hospice)
Pinto, 2020 [97] Italy (Hospital of Reggio Emilia) Prospective cohort No funding 1 February to 3 April 2020; 30 June 2020	Hospitalized with COVID-19 N=1,226 71.7 (14.5) 59.8%	RT-PCR; Electronic health records	Age, sex, cancer type, time from cancer diagnosis, and smoking	ICU admission Mortality
Poletti, 2020 [98] Italy (Lombardy) Prospective cohort Non-industry	People with COVID-19 N=2,824 Median (IQR): 53.0 (34.0- 64.0)	RT-PCR & IgG testing; Database of contacts of COVID-19 patients; ongoing serological survey;	Age, sex, cardiovascular disease (including hypertension, hypercholesteremia, myocardiopathy, heart failure, ischemic and	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
February to April 2020; 8 June 2020	43.2%	linelist of COVID-19 patients	valve cardiopathy, vasculopathy) (as well as epidemic period of observed outcomes)	
Polverino, 2020 [99] Italy (nationwide) Retrospective cohort Non-industry 25 March to 22 April 2020; follow-up within 30 days from data collection	Hospitalized with COVID-19 N=3,179 Median (IQR): 69.0 (57.0-78.0) 68.3%	RT-PCR; Medical charts	Age, sex, number of comorbidities, clustered by hospital site	Mortality (in-hospital)
Portoles, 2020 [100] Spain (Puerta de Hierri University Hospital) Prospective cohort Non-industry 25 February to 24 April 2020 (follow-up NR)	Hospitalized with COVID-19 N=1,603 64.2 (15.6) 59.6%	RT-PCR or clinical & tomography scan criteria; Electronic health records	Age, sex, any comorbidity, previous chronic kidney disease	Mortality (in-hospital)
Poulson, 2020 [101] USA (nationwide) Retrospective cohort Non-industry 5 April to 18 May 2020 (follow-up NR)	People with COVID-19 N=124,780 0-9 y: 0.5% 10-19 y: 1.2% 20-29 y: 9.8% 30-39 y: 13.5% 40-49 y: 14.7% 50-59 y: 18.9% 60-69 y: 17.8% 70-79 y: 12.4% ≥80 y: 11.0% 48.8%	Lab-confirmed (99.0%); CDC Surveillance Review and Response Group	Age, sex, race, comorbidities	Hospitalization ICU admission Mechanical ventilation Mortality
Prado-Galbarro, 2020 [102] Mexico Retrospective cohort No funding 27 February to 27 April 2020; 27 April 2020 (median survival 33 days)	People with COVID-19 N=15,529 ≤40 y: 37.4% >40 y: 62.6% 57.8%	RT-PCR; Mexican Secretary of Health (nationwide COVID- 19 data)	Age, sex, indigenous ethnicity, pneumonia, COPD, immunosuppressive diseases, additional comorbidity, cardiovascular disease, chronic diseases interaction (hypertension, diabetes, obesity, diabetes + hypertension, obesity + hypertension, diabetes + obesity, diabetes + obesity + hypertension), chronic kidney disease	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
			(as well as ICU region density & mode of transport)	
Preston, 2021 [103] USA (189 medical facilities) Retrospective cohort NR 1 March to 31 October 2020	Hospitalized with COVID-19 N=2,430 26% 0-1 years, 10% 2-5 years, 11% 6-11 years, 54% 12-18 years 44.6%	Unspecified lab test; Premier Healthcare Database Special COVID-19 Release	Age, sex, race, presence of a chronic condition, insurance	Severe disease (ICU admission, mechanical ventilation, death)
Price-Haywood, 2020 [104] USA (Louisiana, Ochsner Health) Retrospective cohort NR 1 March to 11 April 2020; 7 May 2020	People with COVID-19 Hospitalized with COVID-19 N=3,481 (1,382 hospitalized) 54.0 (NR) 40.0%	RT-PCR; Electronic health records	Age, sex, race, ethnicity, insurance plan, chronic conditions, BMI, residential zip codes	Hospitalization Mortality (in-hospital)
Rapp, 2020 [105] USA (New York City, Mount Sinai Network) Retrospective cohort Non-industry 29 February to 19 May 2020 (follow-up NR)	Hospitalized with COVID-19 N=4,062 <40 y: 6.6% 40-69 y: 47.9% ≥70 y: 45.5% 57.4%	RT-PCR; Electronic health records (Mount Sinai Hospital System)	Age, sex, asthma, BMI, cancer, COPD, chronic kidney disease, coronary artery disease, HIV, hypertension, smoking (as well as clinical presentation at admission)	Mortality
Reilev, 2020 [106] Denmark (nationwide) Retrospective cohort NR 27 February to 19 May 2020; 30 days follow-up	People with COVID-19 N=11,122 Median (IQR): 48.0 (33.0-62.0) 42.0%	RT-PCR; Danish Microbiology Database and Electronic Health Records	Age, sex, authorized HCW, number of comorbidities, current drug use, medical history, chronic lung disease, hypertension, ischaemic heart disease, heart failure, atrial fibrillation, stroke, diabetes, dementia, any cancer, chronic liver disease, hospital-diagnosed kidney disease, alcohol abuse, substance abuse, major psychiatric disorder, organ transplantation, medical overweight and obesity, rheumatoid arthritis/connective-tissue disease	Hospitalization Mortality
Rentsch, 2020 [107] USA Retrospective cohort	People with COVID-19 N=16,317	Lab-confirmed; US Veterans Health Administration database	Age, sex, race/ethnicity, residence (urban vs. rural), asthma, cancer, chronic kidney disease, chronic pulmonary disease, diabetes,	Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Non-industry 8 February to 21 June 2020; 22 July 2020	20-39 y: 17.0% 40-49 y: 12.0% 50-59 y: 19.0% 60-69 y: 23.0% 89.6%		hypertension, liver disease, vascular disease, substance use (as well as medication history)	
Rey, 2020 [108] Spain (127 centers) Retrospective cohort NR 1 March to 20 April 2020; at least 30 days from diagnosis	People with COVID-19 N=3,080 62.3 (20.3) 54.8%	RT-PCR; Electronic health records	Age, sex, pre-existing conditions	Mortality
Rios-Silva, 2020 [109] Mexico Retrospective cohort No funding 28 February to 25 May 2020; followed up to 60 days for mortality	Women with COVID-19 N=18,390 Median (IQR): 36.0 (29.0- 43.0) 0.0%	RT-qPCR; Mexico Ministry of Health surveillance database	Age, pregnancy status, with individual comorbidities: diabetes, COPD, asthma, immunosuppression, hypertension, obesity, chronic kidney disease, cardiovascular disease, smoking, other comorbidity	Mortality
Rodilla, 2020 [110] Spain (nationwide) Retrospective cohort No funding 1 March to 24 June 2020 (follow-up NR)	Hospitalized with COVID-19 N=12,226 67.5 (16.1) 57.4%	RT-PCR; SEMI-COVID-19 Network	Age, sex, Charlson Comorbidity Index, atrial fibrillation, chronic kidney disease, heart failure, hypertension (as well as prior treatments with ACEIs & ARBs)	Severe disease (invasive/non- invasive ventilation & ICU admission) Mortality (in-hospital)
Samuels, 2021 [111] USA Retrospective cohort No funding 2 March to 31 May 2020; follow-up NR	People with COVID-19 N=1,692 51.0 (19.2) 47.4%	RT-PCR; electronic medical records (Memorial Health System)	Age, sex, race/ethnicity, smoking status, flu vaccine status, comorbidity score, chronic cardiac disease, hypertension, obesity, diabetes, kidney disease, rheumatologic disease, hypothyroidism, dementia, malignant neoplasm, hematologic disease, immunosuppressants (as well as ACE inhibitors, ARBs, spironolactone, immunosuppressant, history of being seen in the past 7 days for symptoms, respiratory rate > 24 breaths/min., temperature ≥ 38.0 °C)	ICU admission

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Sapey, 2020 [112] United Kingdom (University Hospitals Birmingham NHS Foundation Trust) Retrospective cohort Non-industry 10 March to 17 April 2020; 12 May 2020	Hospitalized with COVID-19 N=2,217 Median (IQR): 73.0 (58.0- 84.0) 58.2%	RT-PCR; Electronic health records	Age, sex, race, deprivation index, number of comorbidities	Mortality
Shah, 2020 (a) [113] United Kingdom Retrospective cohort NR 13 March to 15 April 2020; 20 May 2020	Hospitalized with COVID-19 N=1,183 Median (IQR): 71.0 (56.0- 82.0) 57.7%	RT-PCR; Electronic health records (King's College Hospital NHS Foundation Trust)	Age, sex	Mortality
Shah, 2020 (b) [114] Scotland Nested case-control Non-industry 1 March to 6 June 2020; followed for 28 days for mortality	General population N=3,186,184 (181,375 HCW vs household member) Healthcare worker: 44.5 (11.6) Household member: 30.9 (20.9) Healthcare worker: 21.3% Household member: 61.6%	Lab test positive; Scottish Workforce Information Standard System (SWISS); General Practitioner Contractor Database (GPCD); Community Health Index (CHI); REACT-COVID- 19	Age, sex, socioeconomic deprivation, ethnicity, comorbidities, occupation, part-time status	Hospitalization
Tartof, 2020 [115] USA (California) Retrospective cohort Industry 13 Febraury to 2 May 2020; followed for 21 days for mortality	People with COVID-19 N=6,916 49.1 (16.6) 45.0%	Lab-confirmed (82% PCR) or diagnostic codes; Kaiser Permanente Southern California health records	Age, sex, race/ethnicity, comorbidities, substance use, neighborhood-level factors, lab value related to diabetes status, (as well as prior medication and health care use, and time)	Mortality
Ungaro, 2021 [116] USA (Mount Sinai Hospital System, New York) Retrospective cohort Non-industry	People with COVID-19 N=6,792 Median (IQR): 63.0 (51.0-73.0) in inflammatory disease; 62.0 (49.0-74.0) in controls	RT-PCR; Electronic health records	Autoimmune and chronic inflammatory disease (autoimmune hepatitis, ankylosing spondylitis, Sjögren syndrome, scleroderma, psoriasis/psoriatic arthritis, systemic lupus erythematosus, rheumatic arthritis, inflammatory bowel disease, systemic	Mechanical ventilation Severe disease (mechanical ventilation or death) Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
1 March to 12 May 2020; follow-up NR	54.6%		vasculitis, myositis), age, sex, race, comorbidities, obesity	
Valenzuela, 2020 [117] USA (Long Island, New York) Retrospective cohort NR 7 March to 23 May 2020 (follow-up NR)	People with COVID-19 Hospitalized with COVID-19 N=2,039 (996 hospitalized) Median (IQR): 52.0 (38.0-65.0) 53.0%	RT-PCR; Electronic health records	Age, sex, race, clinical symptoms, number of comorbidities, and insurance	Hospitalization ICU admission (among hospitalized) Mechanical ventilation (among hospitalized) Mortality (among hospitalized)
van Gerwen, 2020 (a, b) [118, 119] USA (New York City) Retrospective cohort No funding 1 March to 1 April 2020; 13 May 2020	People with COVID-19 Hospitalized with COVID-19 N=3,703 (2,015 hospitalized) 56.8 (18.2) 55.3%	RT-PCR; Electronic health records	Age, gender, race, BMI, smoking status, and number of comorbidities	Hospitalization Mechanical ventilation (among hospitalized) Mortality (among hospitalized) Severe disease (mechanical ventilation or mortality)
Wang, 2020 [120] USA (New York City) Retrospective cohort No funding 24 February to 15 April 2020; 15 April 2020	People with a COVID-19 hospitalization N=3,273 Median (IQR): 65.0 (53.0- 77.0) 57.3%	RT-PCR & small number by clinical or exposure history; Electronic medical records (Mount Sinai Health System; variables based on self-report, diagnosis code, clinic visit)	Age, sex, race, BMI, smoking status, asthma, COPD, hypertension, obesity, diabetes, HIV, cancer (as well as ICU admission, lab tests duration of stay & vitals)	Mortality (in-hospital)
Yehia, 2020 [121] USA Retrospective cohort NR 19 February to 31 May 2020; 25 June 2020	Hospitalized with COVID-19 N=7,139 Median (IQR): 68.0 (56.0-79.0) 51.3%	PCR; Electronic health records	Age, sex, race, obesity, asthma, chronic kidney disease, COPD, congestive heart failure, coronary artery disease, diabetes, Neighborhood Deprivation Index, insurance	Mortality (in-hospital)
Zafari, 2020 [122] Iran (studies from any country included) Systematic review	β-Thalassemia patients with COVID-19 N=34 Range 21-66 32%	NR; case series	β-Thalassemia	Hospitalization Mechanical ventilation Mortality

Author, year; Country (setting); Study design; Funding Study period; follow-up	Enrolled cohort; Study sample; Mean age (SD), years <sup>a</sup> Male, proportion	COVID-19 Diagnosis; Data source	P <sup>2</sup> ROGRESS risk factors, adjusted for in multivariate regression analysis <sup>b</sup>	Outcomes
Zambrano, 2020 [123] USA Prospective cohort NR 22 January to 3 October 2020; 28 October 2020	Women with COVID-19 N=409,462 15-24 y: 34.1% 25-34 y: 35.4% 35-44 y: 30.6% 0.0%	Lab-confirmed or antigen test; CDC reports through national COVID-19 case surveillance or National Notifiable Disease Surveillance System	Age, race/ ethnicity, and pre-existing conditions, obesity	ICU admission Mechanical ventilation Mortality
Zhu, 2020 [124] United Kingdom Retrospective cohort Non-industry 16 March to 16 April 2020 (follow-up NR)	People with COVID-19 N=489,769 Median (IQR): 58.0 (50.0-63.0) 45.0%	PCR; UK Biobank data	Age, sex, race/ethnicity, cardiovascular disease, diabetes and hypertension, household income	Hospitalization

<sup>&</sup>lt;sup>a</sup> Values for age are mean (SD), unless otherwise specified.

Abbreviations: BMI=body mass index (kg/m²); COPD=chronic obstructive pulmonary disease; HDU=high-dependency unit; HIV=human immunodeficiency virus; ICU=intensive care unit; IQR=interquartile range; NR=not reported; qSOFA=quick sequential organ failure assessment; RT-PCR=reverse transcriptase polymerase chain reaction; SD=standard deviation; y=year(s)

<sup>&</sup>lt;sup>b</sup> Risk factors adjusted for in multivariate analysis may differ for outcome(s) reported within a study.

## B. Characteristics of Canadian reports, n=11

Author year	Participants used in analysis	Risk factors and outcomes	Analysis details
Design (setting, time period)			
Funding source			
Fisman 2020a [125]	1,734 individuals (43% male, median age	Risk factors: age (per 10 year increment); sex;	Multivariate logistic regression
Retrospective cohort (Ontario, Jan-Mar 2020)	55 y, IQR 40 y) from the general population diagnosed with SARS-CoV-2	income; long-term care residency; healthcare worker; homeless shelter worker;	
Funding source: CIHR	via RT-PCR. Data source: iPHIS data	homelessness; smoking; pregnancy status;	
Tunung source. cirik	system.	anemia or hemoglobinopathy; chronic liver	
	System	disease; renal disease; diabetes; COPD;	
		asthma; CVD; malignancy; immune	
		compromised; tuberculosis; obesity (not all	
		adjusted for in analysis).	
		Outcome: mortality in those with COVID-19	
Fisman 2020b [126]	79,498 residents of long-term care	Risk factors: long term care residence	Incidence rate ratio,
Epidemiological cohort	facilities (sex NR, ~93% aged 65+ y) and		denominator for long-term
(Ontario, Mar-Apr 2020)	1,731,315 community-living older adults	Outcome: mortality in population	care based on facility beds;
Funding source: CIHR	(sex NR, aged >69 y). Data source:		stratified by age in community-
	Ontario Ministry of Health and Long-term		dwelling population.
Indigenous Services Canada	Care; Statistics Canada.  9,716 people living on First Nations	Risk factor: place of residence	Descriptive statistics
<b>2021</b> [127]	reserves (sex and age NR) who tested	Nisk factor. place of residefice	Descriptive statistics
Case series (nationwide, Jan	positive for SARS-CoV-2 (diagnostic test	Outcomes: hospitalization & mortality in	
2021)	NR). Data source: Indigenous Services	those with COVID-19	
Funding source: Government of	Canada.		
Canada			
Liu <b>2020</b> [128]	6,431 residents of long term care	Risk factor: long-term care residence	Descriptive statistics
Retrospective cohort (Ontario	facilities (33-36% male, mean age 83-84		
and British Columbia, Jan-Sept	y) who tested positive for SARS-CoV-2	Outcome: mortality in those with COVID-19	
2020)	(diagnostic test NR). Data sources: Public		
Funding source: International	Health Ontario; BC Centre for Disease		
Credential Evaluation Service	Control.	Diel fasten programs	Line diviste divisit vetic
Money 2021 [129] Prospective cohort (British	1,839 pregnant and 136,062 non- pregnant women with COVID-19 (RT-	Risk factor: pregnancy	Unadjusted risk ratio
Columbia, Alberta, Ontario,	PCR). Data source: CAN-COVID Preg	Outcome: hospitalization, ICU admission	
Columbia, Alberta, Ofitario,	database	Outcome. Hospitalization, ICO aumission	

Author year	Participants used in analysis	Risk factors and outcomes	Analysis details
Design (setting, time period) Funding source			
Quebec, Manitoba, March-Dec 2020) Funding sources: PHAC, CIHR, Better Outcomes Registry &			
Network Ontario, BC Women's Health Foundation			
O'Brien 2020a [130] Retrospective cohort (nationwide, Jan-Jul 2020) Funding sources: CIHR, NSERC, York University	100,738 individuals (44% male, age NR) from the general population diagnosed with laboratory-confirmed SARS-CoV-2 (diagnostic test NR) (n=69,409 for mortality, using closed cases). Data source: Statistics Canada COVID-19 dataset; 2016b census to normalize healthcare workforce demographics.	Risk factors: age; sex; healthcare worker  Outcomes: hospitalization, ICU admission & mortality in those with COVID-19	Descriptive statistics, stratified by age and sex
O'Brien 2020b (Statistics Canada) [131] Case series (nationwide, Mar- Jul 2020) Funding source: Statistics Canada	Individuals (sample size, sex, and age NR; 94% ≥65 years) who died from probable or laboratory-confirmed (86%) SARS-CoV-2 (diagnostic test NR). Data sources: Canadian Vital Statistics Death Database.	Risk factors: age; long-term care residence; pre-existing conditions  Outcome: prevalence of conditions among COVID-19 deaths	Descriptive statistics, stratified by age and sex.
Panetta 2020 [132] Retrospective cohort (Montreal, Quebec, Feb-May 2020) Funding source: Réseau SIDA maladies infectueuses grant; Fonds de recherche santé grant.	27 infants <1 year (median 89, range 34- 193 days; 56% male) with laboratory- confirmed SARS-CoV-2 at a single Hospital (Centre hospitalier universitaire Sainte-Justine)	Risk factors: age; sex; comorbid conditions  Outcomes: hospitalization, mechanical ventilation, ICU admission	Descriptive characteristics
PHAC COVID-19 Surveillance and Epidemiology Team 2020 [133] Retrospective cohort (nationwide, Jan-Jul 2020) Funding source: PHAC	106,804 individuals (sex and age NR) from the general population diagnosed with probable or laboratory-confirmed SARS-CoV-2 (diagnostic test NR). Data sources: PHAC; datasets provided by provinces and territories.	Risk factors: age; sex; number of comorbidities (n=6,350); long-term care residence or living in seniors' homes (n=10,150)	Descriptive statistics, stratified by age and/or sex

Author year	Participants used in analysis	Risk factors and outcomes	Analysis details
Design (setting, time period)			
Funding source			
		Outcome: age-standardized mortality in	
		population (for geography), mortality in	
		those with COVID-19 (other risk factors)	
Subedi 2020 (Statistics Canada)	Canadian population. Data sources:	Risk factors: visible minorities (by	Descriptive statistics, stratified
[134]	Canadian Vital Statistics Death Database	neighborhood <1%, 1-<10%, 10-<25%, ≥25%);	by age
Epidemiological cohort	and 2016 Census.	some specific ethnic groups	
(nationwide, Mar-Jul 2020)			
Funding source: Statistics		Outcome: age-adjusted mortality in	
Canada		population	
Wang 2020 [135]	16,490 individuals (45% male, 51% aged	Risk factors: age; sex; long term care	Quasi-Poisson regression for
Prospective cohort (Montreal	<50 y, 21% aged 50-59 y, 14% aged 60-69	residency; living in shelters	residency, adjusting for age
and Toronto, Jan-May 2020)	y) from the general population (including		and sex; also restricted analysis
Funding source: non-industry	long term care residents) diagnosed with	Outcome: mortality in those with COVID-19	to ≥60 y
	laboratory-confirmed SARS-CoV-2		
	(diagnostic test NR). Data sources: iPHIS		

BC=British Columbia; CIHR=Canadian Institutes of Health Research; COPD=chronic obstructive pulmonary disease; CVD=cardiovascular disease; ICU=intensive care unit; iPHIS= Public Health Information System in Ontario; IQR=interquartile range; NR=not reported; NSERC=National Sciences and Engineering Research Council; RT-PCR=reverse transcription-polymerase chain reaction; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; y=years.

## References

- 1. Adrish M, Chilimuri S, Mantri N, Sun H, Zahid M, Gongati S, et al. Association of smoking status with outcomes in hospitalised patients with COVID-19. BMJ Open Resp Res. 2020;7(1):e000716.
- 2. Ahlström B, Frithiof R, Hultstrom M, Larsson I-M, Strandberg G, Lipcsey M. The Swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. Acta Anesthestiol Scand. 2021. 65(4):525-33.
- 3. Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex differences in case fatality rate of COVID-19: Insights from a multinational registry. Mayo Clin Proc. 2020;95(8):1613-20.
- 4. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020;10(1):16726.
- 5. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J Am Coll Cardiol. 2020;76(20):2334-48.
- 6. An C, Lim H, Kim D-W, Chang JH, Choi YJ, Kim SW. Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep. 2020;10(1):18716.
- 7. Anantharaman A, Dusendang JR, Schmittdiel JA, Harzstark AL. SARS-CoV-2 Clinical outcomes in patients with cancer in a large integrated health care system in Northern California. Oncologist. 2021;26(3):e500-e4.
- 8. Anderson MR, Geleris J, Anderson DR, Zucker J, Nobel YR, Freedberg D, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: A retrospective cohort study. Ann Intern Med. 2020;173(10):782-90.
- 9. Attaway AA, Zein J, Hatipoglu US. SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry. EClinicalMedicine. 2020;26:100515.
- 10. Azar KMJ, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California. Health Aff. 2020;39(7):1253-62.
- 11. Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, et al. Assessment of 135794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatrics. 2021;175(2):176-84.
- 12. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-22.
- 13. Bennett KE, Mullooly M, O'Loughlin M, Fitzgerald M, O'Donnell J, O'Connor L, et al. Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: A national surveillance study. Lancet Regional Health. 2021;5(100097).
- 14. Berenguer J, Ryan P, Rodriguez-Bano J, Jarrin I, Carratala J, Pachon J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Mircobiol Infect. 2020;26(11):1525-36.
- 15. Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Aly Z. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol. 2020.

- 16. Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens. PloS One. 2020;15(6):e0235248.
- 17. Carter B, Collins JT, Barlow-Pay F, Rickard F, Bruce E, Verduri A, et al. Nosocomial COVID-19 infection: Examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople). J Hosp Infect. 2020;106(2):376-84.
- 18. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol. 2020;106(2):376-384.
- 19. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307-14.e4.
- 20. Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in Down syndrome: Results from a cohort study Of 8 million adults. Ann Intern Med. 2020;M20-4986
- 21. Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.

  Rheumatol. 2020; keaa897.
- 22. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-70.
- 23. Czernichow S, Beeker N, Rives-Lange C, Guerot E, Diehl JL, Katsahian S, et al. Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients. Obesity. 2020;28(12):2282-9.
- 24. de Azambuja E, Brandao M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on inhospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open. 2020;5(5):e000947.
- 25. Dennis JM, Mateen BA, Sonabend R, Thomas NJ, Patel KA, Hattersley AT, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March-July 2020. Diabetes care. 2021;44(1):50-7.
- 26. Denova-Gutiérrez E, Lopez-Gatell H, Alomia-Zegarra JL, López-Ridaura R, Zaragoza-Jimenez CA, Dyer-Leal DD, et al. The association between obesity, type 2 diabetes, and hypertension with severe COVID-19 on admission among Mexicans. Obesity. 2020;28(10):1826-32.
- 27. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.

- 28. D'Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 Outcomes in Patients with systemic autoimmune rheumatic diseases (SARDs) compared to the general population: A US multi-center comparative cohort study. Arthritis Rheumatol. 2020. doi: 10.1002/art.41619
- 29. Ellington S, Strid P, Tong VT, Woodworth K, Galang R, Zambrano LD, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status United States, January 22–June 7, 2020. Obstet Gynecol Surv. 2020;75(11):664-6
- 30. Esme M, Koca M, Dikmeer A, Balci C, Ata N, Dogu BB, et al. Older adults with coronavirus disease 2019; a nationwide study in Turkey. J Gerontol. 2021. 76(3):e68-75.
- 31. Floyd GC, Dudley JW, Xiao R, Feudtner C, Taquechel K, Miller K, et al. Prevalence of asthma in hospitalized and non-hospitalized children with COVID-19. J Allergy Clin Immunol Pract. 2021. 9(5):2077-9.e2.
- 32. Fond G, Pauly V, Leone M, Llorca P-M, Orleans V, Loundou A, et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: a national cohort study. Schizophr Bull. 2020;sba158.
- 33. Fresan U, Guevara M, Elia F, Albeniz E, Burgui C, Castilla J, et al. Independent role of morbid obesity as a risk factor for COVID-19 hospitalization: a Spanish population-based cohort study. Obesity. 2021;29(1):29-37.
- 34. Garazzino S, Lo Vecchio A, Pierantoni L, Calo Carducci FI, Marchetti F, Meini A, et al. Epidemiology, Clinical Features and Prognostic Factors of Pediatric SARS-CoV-2 Infection: Results From an Italian Multicenter Study. Front Pediatr. 2021;9:649358.139.
- 35. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis. 2020;ciaa1605.
- 36. Giannouchos TV, Sussman RA, Mier JM, Poulas K, Farsalinos K. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. Eur Respir J. 2020;2002144.
- 37. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, et al. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PloS One. 2020;15(8):e0238281.
- 38. Gottlieb M, Sansom S, Frankenberger C, Ward E, Hota B. Clinical course and factors associated with hospitalization and critical illness among COVID-19 patients in Chicago, Illinois. Acad Emerg Med. 2020;27(10):963-73.
- 39. Götzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancella L, Calo Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-61.
- 40. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-55.
- 41. Guerrero-Torres L, Caro-Vega Y, Crabtree-Ramirez B, Sierra-Madero JG. Clinical characteristics and mortality of healthcare workers with SARS-CoV-2 infection in Mexico City. Clin Infect Dis. 2020;ciaa1465.

- 42. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-46.
- 43. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J Am Soc Nephrol. 2020;32(1):161-76.
- 44. Hajifathalian K, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications. Gastroentero. 2020;159(3):1137-1140.e2.
- 45. Hamer M, Gale CR, Kivimaki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci USA. 2020;117(35):21011-3.
- 46. Hamer M, Kivimaki M, Gale CR, David Batty G. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. Brain Behv Immun. 2020;87:184-7.
- 47. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):e100332148.
- 48. Hernández-Vásquez A, Azañedo D, Vargas-Fernández R, Bendezu-Quispe G. Association of comorbidities with pneumonia and death among COVID-19 patients in Mexico: a nationwide cross-sectional study. J Prev Med Public Health. 2020;53(4):211-9.
- 49. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18.
- 50. Huh K, Lee R, Ji W, Kang M, Hwang IC, Lee DH, et al. Impact of obesity, fasting plasma glucose level, blood pressure, and renal function on the severity of COVID-19: A matter of sexual dimorphism? Diabetes Res Clin Pract. 2020;170:108515.
- 51. laccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M, et al. Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension. Hypertension. 2020;76(2):366-72.
- 52. Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk factors for hospitalization, mechanical ventilation, or death among 10131 US veterans With SARS-CoV-2 infection. JAMA Netw Open. 2020;3(9):e2022310.
- 53. Izurieta HS, Graham DJ, Jiao Y, Hu M, Lu Y, Wu Y, et al. Natural History of Coronavirus Disease 2019: Risk Factors for Hospitalizations and Deaths Among >26 Million US Medicare Beneficiaries. J Infect Dis. 2021;223(6):945-56.
- 54. Izzy S, Tahir Z, Cote DJ, Al Jarrah A, Roberts MB, Turbett S, et al. Characteristics and outcomes of Latinx patients with COVID-19 in comparison with other ethnic and racial groups. Open Forum Infect Dis. 2020;7(10):ofaa401.
- 55. Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, et al. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)". Infection. 2021;49(1):63-73.

- 56. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci. 2020;35(25):e237.
- 57. Jiménez E, Fontán-Vela M, Valencia J, Fernandez-Jimenez I, Álvaro-Alonso EA, Izquierdo-García E, et al. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study. BMJ Open. 2020;10(11):e042398.
- 58. Kabarriti R, Brodin NP, Maron MI, Guha C, Kalnicki S, Garg MK, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. JAMA Netw Open. 2020;3(9):e2019795.
- 59. Kaeuffer C, Le Hyaric C, Fabacher T, Mootien J, Dervieux B, Ruch Y, et al. Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. Euro Surveil. 2020;25(48):2000895.
- 60. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2020;ciaa1012.
- 61. Kim T, Roslin M, Wang JJ, Kane J, Hirsch JS, Ji Kim E, et al. Body mass index as a risk factor for clinical outcomes in patients hospitalized with COVID-19 in New York. Obesity. 2020;29(2):279-284.
- 62. King JT Jr., Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PloS One. 2020;15(11):e0241825.
- 63. Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, et al. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J Autoimmun. 2021;120:102632.
- 64. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid obesity as an independent risk factor for covid-19 mortality in hospitalized patients younger than 50. Obesity. 2020;28(9):1595-9.
- 65. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Daily Kirley P, et al. Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2020;ciaa1419.
- 66. Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Med. 2020;17(10):e1003406.
- 67. Kragholm K, Andersen MP, Gerds TA, Butt JH, Ostergaard L, Polcwiartek C, et al. Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) a Danish nationwide, register-based study. Clin Infect Dis. 2020;ciaa924.
- 68. Kummer BR, Klang E, Stein LK, Dhamoon MS, Jette N. History of stroke is independently associated with in-hospital death in patients with COVID-19. Stroke. 2020;51(10):3112-4.

- 69. Kundi H, Cetin EHO, Canpolat U, Aras S, Celik O, Ata N, et al. The role of frailty on adverse outcomes among older patients with COVID-19. J Infect. 2020;81(6):944-51.
- 70. Lassale C, Gaye B, Hamer M, Gale CR, Batty GD. Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun. 2020;88;44-9.
- 71. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psych. 2020;7(12):1025-31.
- 72. Lee S-G, Park GU, Moon YR, Sung K. Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database. International journal of environmental research and public health. 2020;17(22).
- 73. Lee SH, Park S-Y, Seon J-Y, Jeon W-H, Nam S-I, Park J-H, et al. Intensive care unit capacity and its associated risk factors during the COVID-19 surge in the Republic of Korea: analysis using nationwide health claims data. Risk Manag Healthc Policy. 2020;13:2571-81.
- 74. Leon-Abarca JA. Obesity and immunodeficiencies are the main pre-existing conditions associated with mild to moderate COVID-19 in children. Pediatr Obes. 2020;15(12):e12713.
- 75. Loffi M, Piccolo R, Regazzoni V, Di Tano G, Moschini L, Robba D, et al. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. Open Heart. 2020;7(2).
- 76. Ludvigsson JF, Axelrad J, Halfvarson J, Khalili H, Larsson E, Lochhead P, et al. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United European Gastroenterol J. 2021. 9(2):177-92.
- 77. Lunski MJ, Burton J, Tawagi K, Maslov D, Simenson V, Barr D, et al. Multivariate mortality analyses in COVID-19: comparing patients with cancer and patients without cancer in Louisiana. Cancer. 2021;127(2):266-74.
- 78. Mallow PJ, Belk KW, Topmiller M, Hooker EA. Outcomes of hospitalized COVID-19 patients by risk factors: results from a United States hospital claims database. J Health Econ Outcomes Res. 2020;7(2):165-74.
- 79. Mancilla-Galindo J, Vera-Zertuche JM, Navarro-Cruz AR, Segura-Badilla O, Reyes-Velazquez G, Tepepa-Lopez FJ, et al. Development and validation of the patient history COVID-19 (PH-Covid19) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19. Epidemiol Infect. 2020;148:e286.
- 80. Martinez-Portilla RJ, Smith ER, He S, Torres-Torres J, Espino-Y-Sosa S, Solis-Paredes JM, et al. Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019: analysis of the Mexican National Surveillance Program. Am J Obstet Gynecol. 2021;224(4):404-7.
- 81. Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, Torres-Torres J, Espino Y Sosa S, Sandoval-Mandujano K, et al.

  Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021;57(2):224-31.

- 82. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med. 2020;36:17-26.
- 83. Miller J, Fadel RA, Tang A, Perrotta G, Herc E, Soman S, et al. The impact of sociodemographic factors, comorbidities and physiologic response on 30-day mortality in COVID-19 patients in Metropolitan Detroit. Clin Infect Dis. 2020;ciaa1420.
- 84. Misra-Hebert AD, Jehi L, Ji X, Nowacki AS, Gordon S, Terpeluk P, et al. Impact of the COVID-19 pandemic on healthcare workers' risk of infection and outcomes in a large, integrated health system. J Gen Intern Med. 2020;35(11):3293-301.
- 85. Molnar MZ, Bhalla A, Azhar A, Tsujita M, Talwar M, Balaraman V, et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Translant. 2020;20(11):3061-71.
- 86. Moreira A, Chorath K, Rajasekaran K, Burmeister F, Ahmed M, Moreira A. Demographic predictors of hospitalization and mortality in US children with COVID-19. Eur J Pediatr. 2021;180(5)1659-63.
- 87. Murillo-Zamora E, Hernandez-Suarez CM. Survival in adult inpatients with COVID-19. Public health. 2021;190:1-3.
- 88. Nachtigall I, Lenga P, Jozwiak K, Thurmann P, Meier-Hellmann A, Kuhlen R, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect. 2020;26(12):1663-9.
- 89. Nair V, Jandovitz N, Hirsch JS, Abate M, Satapathy SK, Roth N, et al. An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. Am J Transplant. 2020. doi: 10.1111/ajt.16460.
- 90. Nijman G, Wientjes M, Ramjith J, Janssen N, Hoogerwerf J, Abbink E, et al. Risk factors for in-hospital mortality in laboratory-confirmed COVID-19 patients in the Netherlands: A competing risk survival analysis. PloS One. 2021;16(3):e0249231.91.
- 91. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6);1530-9.
- 92. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol. 2020;52:93-8.e2.
- 93. Parra-Bracamonte GM, Parra-Bracamonte FE, Lopez-Villalobos N, Lara-Rivera AL. Chronic kidney disease is a very significant comorbidity for high risk of death in patients with COVID-19 in Mexico. Nephrol. 2020. 26(3):248-51.
- 94. Patel AP, Paranjpe MD, Kathiresan NP, Rivas MA, Khera AV. Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. Int J Equity Health. 2020;19(1):114.
- 95. Petermann-Rocha F, Hanlon P, Gray SR, Welsh P, Gill JMR, Foster H, et al. Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank. BMC Med. 2020;18(1):355.

- 96. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
- 97. Pinto C, Berselli A, Mangone L, Damato A, Iachetta F, Foracchia M, et al. SARS-CoV-2 positive hospitalized cancer patients during the Italian outbreak: the cohort study in Reggio Emilia. Biology. 2020;9(8):181.
- 98. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. Euro Surveill. 2020;25(31):2001383.
- 99. Polverino F, Stern DA, Ruocco G, Balestro E, Bassetti M, Candelli M, et al. Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian observational study (ItaliCO). Front Cardiovasc Med. 2020;7:585866.
- 100. Portolés J, Marques M, López-Sánchez P, de Valdenebro M, Muñez E, Serrano ML, et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant. 2020;35(8):1353-61.
- 101. Poulson M, Geary A, Annesi C, Allee L, Kenzik K, Sanchez S, et al. National disparities in COVID-19 outcomes between Black and White Americans. J Natl Med Assoc. 2020; in press.
- 102. Prado-Galbarro FJ, Sanchez-Piedra C, Gamino-Arroyo AE, Cruz-Cruz C. Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients. Pub Health. 2020;189:66-72.
- 103. Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open. 2021;4(4):e215298.
- 104. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382:2534-43.
- 105. Rapp J, Lieberman-Cribbin W, Tuminello S, Taioli E. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest. 2020;159(1):112-5.
- 106. Reilev M, Kristensen KB, Pottegard A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468-81.
- 107. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Jr., Skanderson M, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med. 2020;17(9):e1003379.
- 108. Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejon-Castrejón S, Marco-Clement I, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020:101002/ejhf.1990.
- 109. Ríos-Silva M, Murillo-Zamora E, Mendoza-Cano O, Trujillo X, Huerta M. COVID-19 mortality among pregnant women in Mexico: A retrospective cohort study. J Glob Health. 2020;10(2):020512.

- 110. Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of Hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med. 2020;9(10):3136.111.
- 111. Samuels S, Niu J, Sareli C, Eckardt P. The epidemiology and predictors of outcomes among confirmed COVID-19 cases in a large community healthcare system in South Florida. J Community Health. 2021. doi: 10.1007/s10900-020-00957-y
- 112. Sapey E, Gallier S, Mainey C, Nightingale P, McNulty D, Crothers H, et al. Ethnicity and risk of death in patients hospitalised for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. BMJ Open Resp Res. 2020;7(1):e000644.
- 113. Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ. 2020;371:m3582.
- 114. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):279-82.
- 115. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173(10):773-81.
- 116. Ungaro RC, Agrawal M, Park S, Hirten R, Colombel J-F, Twyman K, et al. Autoimmune and chronic inflammatory disease patients with COVID-19. ACR Open Rheumatol. 2021;3(2):111-5.
- 117. Valenzuela RG, Michelen Y, Bracey A, Cruz P, Fombonne B, Fries BC, et al. Outcomes in Hispanics With COVID-19 are similar to those of Caucasian patients in suburban New York. Acad Emerg Med. 2020;27(12):1260-9.
- 118. van Gerwen M, Alsen M, Little C, Barlow J, Genden E, Naymagon L, et al. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol. 2020;93(2):917-15.
- 119. van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, et al. Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol. 2020;11:565.
- 120. Wang Z, Zheutlin A, Kao Y-H, Ayers K, Gross S, Kovatch P, et al. Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. BMJ Open. 2020;10(10):e040441.
- 121. Yehia BR, Winegar A, Fogel R, Fakih M, Ottenbacher A, Jesser C, et al. Association of race with mortality among patients hospitalized with Coronavirus Disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open. 2020;3(8):e2018039.
- 122. Zafari M, Rad MTS, Mohseni F, Nikbakht N. β-Thalassemia Major and boronavirus-19, mortality and morbidity: a systematic review study. Hemoglobin. 2020:1-8.

- 123. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641-7.
- 124. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism. 2020;112:154345.
- 125. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk factors associated with mortality among residents with Coronavirus Disease 2019 (COVID-19) in long-term care facilities in Ontario, Canada. JAMA Netw Open. 2020;3(7):e2015957.
- 126. Fisman DN, Greer AL, Hillmer M, Tuite R. Derivation and validation of clinical prediction rules for COVID-19 mortality in Ontario, Canada. Open Forum Infect Dis. 2020;7(11):ofaa463.
- 127. Indigenous Services Canada. Confirmed cases of COVID-19. Ottawa ON: Indigenous Services Canada; 2021. Available from: https://www.sac-isc.gc.ca/eng/1598625105013/1598625167707.
- 128. Liu M, Maxwell CJ, Armstrong P, Schwandt M, Moser A, McGregor MJ, et al. COVID-19 in long-term care homes in Ontario and British Columbia. CMAJ. 2020;192(47):E1540-E6.
- 129. Money D. Canadian surveillance of covid-19 in pregnancy: Epidemiology, maternal and infant outcomes. Vancouver, Canada: University of British Columbia; 2021.
- 130. O'Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age.

  J Ovarian Res. 2020;13(1):137.
- 131. O'Brien K, St-Jean M, Wood P, Willbond S, Phillips O, Currie D, et al. COVID-19 death comorbidities in Canada.

  Ottawa, Canada: Statistics Canada; 2020. Available from: https://www150.statcan.gc.ca/n1/en/pub/45-28-0001/2020001/article/00087-eng.pdf?st=Tj531x2z
- 132. Panetta L, Proulx C, Drouin O, Autmizguine J, Luu TM, Quach C, et al. Clinical Characteristics and Disease Severity Among Infants With SARS-CoV-2 Infection in Montreal, Quebec, Canada. JAMA Netw Open. 2020;3(12):e2030470.
- 133. Public Health Agency of Canada COVID-19 Surveillance and Epidemiology Team. Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020. Canada Communicable Disease Report (CCDR). 2020;46(10):344-8.
- 134. Subedi R, Greenberg G, Turcotte M. COVID-19 mortality rates in Canada's ethno-cultural neighbourhoods. Ottawa, Canada: Statistics Canada; 2020. Available from: https://www150.statcan.gc.ca/n1/pub/45-28-0001/2020001/article/00079-eng.htm
- 135. Wang L, Ma H, Yiu KCY, Calzavara A, Landsman D, Luong L, et al. Heterogeneity in testing, diagnosis and outcome in SARS-CoV-2 infection across outbreak settings in the Greater Toronto Area, Canada: an observational study. CMAJ Open. 2020;8(4):E627-E36.